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Changes in blood pressure from high to low are genetically and environmentally 
controlled. In humans, linkage analysis and GWAS has pointed out to various regions on 
human chromosome 17 that are linked to blood pressure regulation. Linkage studies in 
particular, also document that the inheritance of complex traits is not always as a result of 
mutation/s within several or single genes but may also be due to interactions within genetic 
determinants. To study this complex aspect of blood pressure regulation, rat models are 
used. Linkage analysis in rats has led to identification of large segments of chromosome 5 
and 10 containing large number of candidates. Hence substitution mapping is used to 
generate and test progressively shorter genomic segments within congenic strains and 
thereby facilitate the examination of smaller number of candidates.  
Substitution mapping study on rat chromosome 5 shows that epistasis plays a major 
role in blood pressure regulation and missing this aspect in GWAS study can lead to 
missing of those determinant in human studies that do not play a direct role in regulation 
of blood pressure.  
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Additionally, mapping studies on rat chromosome 10 which shows homology to 
human chromosome 17, has been used to demonstrate that there could be novel regions on 
human chromosome 17 currently annotated as gene deserts but have not yet been identified 
as containing determinants of blood pressure regulation.  
The two studies are examples that animal models of hypertension are tools to help 
find variations on the human genome that are relevant in regulation of complex traits like 
blood pressure.  
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Chapter 1 
Literature review 
 
 
1.1 Blood Pressure 
 
Blood pressure or arterial blood pressure is measured by the force or pressure exerted 
by blood on the walls of the arteries and is expressed as millimeters of mercury (mmHg). 
It is calculated as the product of cardiac output (volume of blood pumped by each ventricle 
per minute) and total peripheral resistance (the overall resistance to blood flow through the 
systemic blood vessels).   At the basic level, BP is controlled by only two variables 
following Ohm's law: peripheral vascular resistance (influenced by factors like arterial wall 
modifications due to ageing, medial hypertrophy due to hyperinsulinaemia or obesity) and 
blood flow (modified by, e.g. increased fluid volume due to increased salt intake) [1]. 
Changes in blood pressure are physiologically done to direct appropriate amounts of 
oxygen and nutrients to specific parts of the body based on specific needs.  
There are two mechanisms for regulating BP:  
1) Short term mechanism which involves activation/inactivation of baroreceptors in 
the large arteries like carotid sinus and aortic arch in response to an 
increase/decrease of BP. The baroreceptors signals the brain to decrease/increase 
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sympathetic activity and increase/decrease parasympathetic activity causing the 
heart rate to decrease/increase and arterial diameter to increase/decrease leading to 
lowering/rise in  BP.  Short term lowering of osmolarity by dehydration signals the 
thirst centers in the brain to increase the intake of water thus restoring osmolarity 
and rehydrate and maintain blood volume thus restoring BP. 
 
2) Long term mechanism- This is done by regulating blood volume in the body after 
blood loss through hemorrhage, accidents or blood donation leading to lower BP. 
The juxtaglomerular cells in the kidney recognize the failing BP and releases renin 
into the bloodstream. Renin causes angiotensin II to be released from angiotensin I 
and angiotensin II causes release of aldosterone from the adrenal glands located 
above the kidney. Angiotensin II is also a powerful vasoconstrictor and helps to 
increase BP by itself. Aldosterone leads to increased sodium and water reabsorption 
in the renal tubules which inturn leads to increased BP.  
Incase of excessive dehydration, an increase in blood osmolarity and decrease in 
BP, the hypothalamus signals the posterior pituitary to release antidiuretic hormone 
(ADH) that increases reabsorption of water in the kidney by increasing the number 
of water channels in the distal convoluted tubules and collection duct. This leads to 
an increase in blood volume and hence an increase in BP. 
Fluctuations in blood pressure are normal and the body functions to handle it 
effectively. But when there is persistently low or high blood pressure, it is called as 
hypotension or hypertension respectively. Hypotension is when the blood pressure 
readings are lower than 90 mm Hg systolic or 60 mm Hg diastolic or normal systolic 
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but low diastolic. It can cause dizziness, weakness and a risk of injury from falls. 
Severe forms of hypotension can cause the brain to receive an inadequate supply of 
blood and oxygen to carry out its normal functions, leading to damage to your heart 
and brain. Since hypertension is more common and dangerous it is discussed in 
detail below. 
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1.2 Hypertension 
 
In as many as 95% of reported high blood pressure cases in the U.S., the underlying 
cause cannot be determined. High BP in which secondary causes like renal failure, 
renovascular disease, aldosteronism or other causes are not present is called primary, 
idiopathic or essential hypertension.  In adults, it is diagnosed when the average of two or 
more diastolic BP measurements on atleast two subsequent visits is >90 mmHg or when 
the average systolic BP of two or more subsequent visit is >140 mmHg. Isolated systolic 
hypertension is defined as systolic BP of >140mmHg and diastolic BP of <90 mmHg. This 
definition is given in the sixth report of the Joint National Committee on Prevention, 
Detection, Evaluation and Treatment of High BP (JNC IV) [2].  
There is a strong correlation between high blood pressure and cardiovascular disorders 
like stroke, myocardial infarction, renal disease and death. In America, 67 million adults 
(31%) have high blood pressure but only 47% of this population have it under control and 
management of high blood pressure costs the nation $47.5 billion each year. The factors 
that influence high BP are [3]: 
1. Age and Gender- In an age group of individuals < 45 years old, hypertension is 
more prevalent in males than females. For people 65 years old or older, high blood 
pressure affects more women than men. 
2.  Race- The incidence of high BP is highest among African Americans (43% in 
males and 45.7% in females) and lowest among the white population (33.9% in 
males and 31.3% in females). 
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3. Lifestyle and socioeconomic status- Lack of physical exercise, tobacco and alcohol 
consumption, unhealthy diet and obesity. 
4. Geographic patterns- Hypertension is more prevalent in the southeastern parts of 
the United States [2]. 
 
Different forms of Hypertension: 
 
There are two major types of hypertension and four less frequent ones: 
1. Primary or essential hypertension- It is diagnosed in the majority of the patients and 
there is no known cause. It may tend to develop gradually over the years. 
2. Secondary hypertension- It is often caused due to various conditions which may 
include: Kidney diseases, adrenal gland tumors, thyroid imbalances, congenital 
defects of the blood vessels, certain prescription drugs and birth control pills, 
alcohol and/or drug abuse and sleep apnea. 
3. Malignant hypertension- It is severe and progressive and may lead to organ damage 
unless properly treated. 
4. Isolated systolic hypertension- in this case the BP is consistently above 160 mm 
Hg, and the diastolic below 90 mm Hg. It usually occurs in older people, and results 
from the age-related stiffening of the arteries mostly due to arteriosclerosis.  
5. White coat hypertension- Also known as anxiety-induced hypertension. The high 
BP develops only when tested by a health professional and may not need any 
treatment.   
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6. Resistant Hypertension- If BP is not reduced to below 140/90 mmHg despite a 
triple-drug regime, resistant hypertension is considered. 
 
 Essential hypertension: what is known? 
 
Essential hypertension has its roots in two important factors: Genetic factors that determine 
predisposition to an increase in blood pressure and extrinsic factors like high salt intake, 
alcohol intake, obesity, stress, low calcium and potassium in diet, insulin resistance, age 
and sedentary lifestyle. So, if an individual inherits normal BP and adds one or more of the 
extrinsic factors, the BP rises but stays within normal range. If an individual has inherited 
high BP but within the normal range and adds extrinsic factors, he may increase his BP to 
the hypertensive stage. In addition increasing the number of extrinsic factors to a 
hypertensive genetic background may increase the persons BP to a severely hypertensive 
range. Knowing the contributing extrinsic factors can help control or correct the BP 
increase. Hence, in a constant or ideal environment, determination of the genetic factors 
must be done in order to control the BP increase in a patient to prevent contributing risk 
factors [2, 4]. 
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1.3 Current treatment of hypertension 
 
Changes in lifestyle- Lowering sodium and alcohol intake, keeping weight in the ideal 
range, engaging in regular aerobic exercise, and ending smoking can help some people to 
control high blood pressure. Reduction in sodium intake (less than 2.3 grams per day), can 
also work effectively as therapy along with one blood pressure-lowering drug [5-9] 
The current medications include [10-13]: 
Diuretics- Causes the kidneys to excrete more sodium and water, reducing fluid volume 
throughout the body and dilates blood vessels. The common diuretic used is thiazides and 
in some cases, a potassium supplement or a potassium-sparing diuretic is given in 
combination with a thiazide diuretic to counter the potassium deficiency caused due to its 
increased excretion in the urine [14-17]. 
ACE inhibitors- Angiotensin II causes the blood vessels to constrict and BP to increase. 
Angiotensin-converting enzyme (ACE) inhibitors block production of the hormone, 
angiotensin II and allow blood vessels to dilate and helps to lowers blood pressure [18-21]. 
Angiotensin II receptor blockers- The angiotensin II receptor blockers (ARBs) block the 
effects of angiotensin II on cells in the heart and blood vessels. This helps in dilating blood 
vessels, lower blood pressure, and improve heart output [20, 21]. 
Calcium channel blockers- CCBs block the calcium channels and limit the amount of 
calcium that enters the smooth muscle in blood vessel walls and heart muscle. They reduce 
contraction of vascular smooth muscle and reduce contraction causing vasodilation. In the 
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myocardium they reduce force of contraction and also slow the conduction of electrical 
activity within the heart causing slowing down of heart beat. By blocking the calcium 
signal on adrenal cortex cells, they directly reduce aldosterone production, and hence lower 
blood pressure [18, 19, 21]. 
Beta blockers- Beta blockers block some of the effects of the  sympathetic nervous system-  
endogenous catecholamine epinephrine (adrenaline) and norepinephrine (noradrenalin), 
which helps in increasing the heart rate and raising blood pressure during a fight or flight 
response. This is done by decreasing the rate and force at which the heart pumps blood [22-
24]. 
Alpha blockers — Alpha blockers relax or reduce the tone of involuntary vascular smooth 
muscle in the walls of blood causing vasodilation, thereby lowering blood pressure [25].  
Direct vasodilators — Direct vasodilators relax or reduce the tone of blood vessels but 
are used only in case of severe or resistant high blood pressure [26] [27]. 
Since hypertension is a multifactorial disease, treating all hypertensive patients using the 
same drugs or similar cocktail of drugs may not often result in the control of BP. This is 
because the reason for development of hypertension is different in different individuals as 
is the genetic variants responsible for this change in BP. This idea of personalized medicine 
is not very new and has been published in a JNC report in 1977[28]. Personalized medicine 
refers to the use of diagnostic and screening methods that use the knowledge of the patient’s 
unique molecular and risk profile to improve the management of the patient’s disease or 
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predisposition towards it. The ability and availability of the tools to characterize the 
individual differences at the molecular level has made this concept more realistic. [28-31] 
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1.4 Genetics of hypertension  
Although much is known about BP regulation and the environmental factors regulating 
it,  the intrinsic origin of essential hypertension remains obscure [32]. The genetic influence 
on a trait like BP is expressed in terms of heritability and is measured as the fraction of the 
total interindividual variability attributed to the genes that is inherited [33]. Previous 
epidemiological and familial studies and history of affected individuals along with disease 
inheritance rate in twins has established that there is a complex interaction between both 
genetic and environmental factors that determine susceptibility to hypertension [34-36]. 
Hypertension is about twice as common in subjects who have one or two hypertensive 
parents [37]. The heritability of hypertension is often cited in the range of 30% - 60%, with 
multiple contributory genes. This of course should not be taken to imply that the remainder 
is environmental, as gene–environment interactions are essential yet irresolvable part of 
the variability in the development of hypertension. Other factors like ethnicity and genetic 
heterogeneity add to the variability in clinical presentation and drug response in 
hypertension making the genetic study of this disease challenging [36, 38, 39].  
 
It is known that genetic variants play an important role in the origin of essential 
hypertension reflecting the characteristics of the complex genetic trait that BP is known 
for. The variations in the genome can be single-nucleotide polymorphisms (SNPs) and 
consists of two or rarely more different possible nucleotide bases (alleles) at the same 
genetic position [40]. Other types of variation of the human genome are insertions and 
deletions (INDELS), structural variation (Copy Number Variations CNV), or epigenetic 
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modification [41-44]. The variations can be tested by genotyping for the variations and 
sequencing. 
 
Hypertension as a monogenic trait 
 
Certain studies have shown that hypertension maybe inherited as a simple 
Mendelian trait. Such inheritance patterns may indicate the presence of monogenic forms 
of hypertension that occurs in rare families are due to rare variants with a large effect [45]. 
Early onset at a relatively young age or early adolescence may indicate inheritance of a 
dominant condition while consanguinity (inheritance in first cousins) may indicate 
recessive inheritance. All monogenic forms of hypertension are marked by specific 
phenotypic features, such as electrolyte and hormonal abnormalities like suppression of the 
renin–angiotensin system (low plasma renin level or activity) due to expansion in plasma 
volume. In addition to hyporeninemia, hypouricemia (decreased uric acid in blood serum 
by reducing its proximal tubular reabsorption) and hypokalemia are also present [33, 46-
48]. Table 1.1 suggests the molecular basis for known monogenic hypertension syndromes 
[49-63]. Hence, the lesson from monogenic hypertension research is that the 12 genes are 
members of only two groups of pathways: renal sodium handling and steroid hormone 
metabolism, including mineralocorticoid receptor activity and most of the genetic 
abnormalities are present in the proteins related to the kidney and steroid hormone activity. 
But these rare variants near genes implicated in monogenic hyper- and hypotension and are 
very low in frequency in the general population and therefore unlikely to explain much of 
the BP variation in the general population and therefore hypertension. Our findings in 
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Mendelian forms of hypertension genes do, therefore, not appear to significantly help in 
the understanding of the pathogenesis of essential hypertension [45].  
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Table 1.1- Mendelian forms of hypertension- Different known heritable forms of arterial 
hypertension 
 
Monogenic syndrome 
Mode of 
inheritance 
Gene mutations 
Location in 
chromosome 
Liddle’s syndrome 
(pseudoaldosteronism) 
Dominant 
SCNN1B or SCNN1G 
16p 
Apperent 
mineralocorticoid excess 
(AME) 
Recessive 
11β-HSD-2 
16q 
Congenital adrenal 
hyperplasia- 11-β and17-α 
hydroxylases type 
Recessive 
Nonfunctional 
hydroxylases CYP11B1 
and CYP17A 
8q and 10q 
Glucocorticoid remediable 
aldosteronism (GRA) 
Recessive/ 
Dominant 
CYP11B1 (11 -
hydroxylase)/ 
CYP11B2 (aldosterone 
synthase) 
8q/8p 
Gordon’s syndrome 
(Pseudohypo 
aldosteronism type II) 
Dominant 
WNK1 / WNK4 
 
12p / 17q 
Familial 
hyperkalemic hypertension 
 KLHL3 / CUL3 5q / 2q 
Early-onset autosomal 
dominant HTN with 
exacerbation in pregnancy 
Dominant NR3C2 4q 
Familial 
hyperaldosteronism type 
III 
Dominant 
 
KCNJ5 11q 
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Hypertension as a polygenic trait 
 
The nature of hypertension has been debated by Platt and Pickering where Platt 
thought that hypertension was a simple disease caused by a single genetic defect that was 
autosomal dominant and inherited. He thought that the distribution was bimodal indicating 
that hypertensives were a distinct subpopulation in humans [64]. Some familial forms of 
hypertension are inherited as single‐gene disorders, but they are a small proportion of the 
total cases. In contrast, Pickering's thought that blood pressures varied constantly and 
shows continuous and unimodal distribution. This model of multiple susceptibility genes 
along with environmental interaction is one that can be applied to other common diseases 
including asthma, diabetes and ischaemic heart diseases. Therefore Pickering’s view of 
polygenic basis for BP in the general population is widely accepted and is the basis of 
current understanding and treatment policies [33, 65, 66].  
Since BP is a continuous variable [67] and the effect of a single factors like one 
gene may be small, the current task is to identify variations in genetic elements like protein 
coding genes, protein noncoding elements, regulatory elements that may independently or 
in combination modulate BP. 
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1.5 Human genetic studies of hypertension 
The nature of essential hypertension has always been elusive since it was first described 
in 1877. Historically in human, the genetics of hypertension presents a stark contrast 
between the high heritability of blood pressure and hypertensive traits and the reality that 
no clearly reproducible genetic variant for essential hypertension could be found [68]. The 
methods used to find the genetic elements responsible for changing blood pressure or 
hypertension have been 1) Candidate gene approach, 2) Genome wide linkage studies and 
3) Genome wide association studies (GWAS) 
 
Candidate Gene Approach- Several efforts have been made to study the genes linked to 
hypertension and the candidate gene approach is one such method. The method uses 
polymorphisms in a subset of genes that have previously been studied to play a role in 
blood pressure regulation. The limited number of polymorphisms leads to detection of 
small effects using a moderate sample size. The drawback of this method is that it ignores 
epistasis (for example, Pascoe et al [69] provided evidence of intragenic interactions in the 
aldosterone synthase gene where subjects with two missense mutations show elevated 
serum ratio of 18-hydroxycorticosterone to aldosterone while those with only one mutation 
were asymptomatic), gene environment interaction (for example significant BP 
interactions were found in a study where physically active subjects who had SNPs in MR, 
SCNN1B, APLNR, GNB3 and BDKRB2 showed a reduction of upto 8mm Hg in systolic 
BP and 5mm Hg in diastolic BP compared to inactive individuals who carry the same 
variants [69-75] and rare variant effects [76, 77]. This may lead to inconsistent findings 
and associations that are not well replicated across studies [78-80]. Another disadvantage 
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of the method is that the proportion of the genes that are associated with a particular trait 
is small and hence the list of candidate genes is limited [81]. 
 
Genome Wide Linkage studies- On the human genome, two loci are linked because of 
their physical connection on the piece of DNA and if they are close to each other, the alleles 
tend to cosegregate within families. Such cosegregating haplotypes are broken up by 
recombination. If two loci are close to each other, the probability of a recombination 
between two loci becomes low, conversely, recombination occurs more frequently between 
loci that are far apart. Thus, recombination is a function of the distance between the two 
loci, although not a linear relationship. The search for genes related to a disease trait begins 
with linkage analysis. The aim of the method is to determine the approximate location of a 
gene using DNA sequences called genetic markers that show polymorphism and whose 
position is already known. This is illustrated in Figure 1-1.  
The principle of linkage analysis is that in the case of a diseased gene, one of the two 
alleles (either from the mother or father) will contain the disease allele. The alternate allele 
will be normal. During meiosis when recombination occurs either the paternal and maternal 
alleles will mix up due to the large distance between them (see A and C in Figure1-1) or 
they can recombine and stay together (see A and B in the Figure1-1). Hence the diseased 
genes can be mapped by measuring recombination against a series of different genetic 
markers spread over the genome. If the marker and the diseased gene lie in proximity to 
each other, they will not recombine and hence is said to be linked to it.   Ideally, those 
genetic markers are identified that flank the disease gene and hence define a candidate 
region of the genome [82].  
17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1 Chromosomal recombination between the maternal (red) and paternal 
(blue) during meiosis. The three points A, B, C and a, b, c are DNA markers on the 
paternal and maternal alleles respectively. The recombined chromosome is then passed 
on to the offsprings. If A is the diseased gene and B and C are the DNA markers, then 
recombination is most likely to occur between A and C rather than Aand B. Hence we 
can use the two markers B and C to map the relative position of A.  
 
 
 
 
 
 
 
Adapted with permission from http://genome.wellcome.ac.uk  
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Genetic linkage analysis is a statistical method that is used to associate functionality 
of genes to their location on chromosomes. Linkage is expressed as a statistic, LOD 
score (Z); a “logarithm of odds” [83].  
 
 LOD score = log10   
        
              
The LOD scores are calculated at many selected points in an interval between 
markers and plotted versus the map position. The term Quantitative Trait Loci is used 
to describe a broad region on the chromosome that may contain one or more loci 
controlling or participating in controlling the quantitative trait like BP. The QTL effect 
enters the likelihood equations through the observed BP data and the QTL map 
position. 
Positive values of Z suggest that two loci are linked and negative values suggest 
that two loci are not linked. By convention, a LOD score of +3 or greater is considered  
evidence that two loci are linked. A LOD score below -2 excludes linkage [84] The 
LOD scores can then be used to obtain the LOD plot. The evidence of association 
between an allele and a phenotype can be due to: 1) The allele can directly affect the 
phenotype because it is functional 2) the given allele is correlated or is in linkage 
disequilibrium with the neighboring causative allele or 3) The association with the trait 
could be an artifact or coincidence.  
Association studies are usually performed in a case control cohort format ensuring 
that the controls are true controls and dividing the population into subgroups play a 
Likelihood of Linkage of loci 
 
Likelihood that loci are unlinked 
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major role [85-87]. The British Genetics of Hypertension (BRIGHT), one of the largest 
genome wide linkage scans reported a QTL on the end of chromosome 6 [88] and on 
chromosome 5 [89] in sibling pairs of white British ancestry. The metabolic syndrome 
factor scores were derived in 4 ethnic groups recruited in 3 Networks of the Family 
Blood Pressure Program (FBPP): GENOA (blacks, Hispanics, and whites), HyperGEN 
(blacks and whites), SAPPHIRe (Asians). Results from HyperGEN reported a locus on 
chromosome 2 in the African American sibpairs [90] and GenNet reported a Significant 
QTL on chromosome 1 which was later reproduced by GENOA and HyperGEN [91-
94].  
 Multiple linkage studies have reported QTLs linked to BP on human chromosome 
17. In 1997, Cécile Julier et. al studied a panel of 357 French and UK families 
containing 384 sibships with one or more hypertensive offsprings and a total of 518 
affected sib-pairs and found a strong support for linkage at marker D17S183 [95]. In 
1999 Xu et.al. did a blood-pressure screening of >200,000 Chinese adults, sib pairs and 
found a BP associated QTL with a LOD score of 2.16 near the marker D17S1303 
(GATA64B04) [96]. In 2000, Rice et al conducted the Que´bec Family study consisting 
of 206 families including 335 sibpairs and found nominal probability values on human 
chromosome 17 in the region of 17q21.33-17q21.2 [97]. Similarly, using a 10-cM 
density genome-wide scan in participants from the Framingham Heart Study, Levy et.al 
found significant evidence of linkage of longitudinal systolic BP to chromosome 
17q12–21, at markers GATA25A04 (D17S1299) and ATC6A06 [D18S481] with a 
LOD score of 4.7 [98, 99]. Further, Rutherford et.al in a study using 177 affected adult 
Caucasian sibpairs of British descent living in Australia, reported a BP QTL on 
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chromosome 17 between markers D17S949 (68465676) and D17S799 (13,170,963) 
[100]. A BP QTL was located on chromosome 17q23.1 with a peak located at the 
marker GATA49C09 (D17S1290) in the hispanic population in the GENOA study. 
HyperGEN shows a lower LOD scores for linkage to BP around the same region in the 
Chinese and Japanese as well as the white population. A1-lod score interval around the 
linkage peak for candidate genes indicates the Angiotensin I Converting Enzyme (ACE) 
gene as the probable candidate [101, 102]. To study the genetic factors and to localize 
sex-specific BP quantitative trait loci (QTL), Franceshini et.al conducted a genome 
scan using American Indian participants of the Strong Heart Family Study. Systolic 
blood pressure of both genders were collected separately and combined for the study. 
A suggestive linkage was observed in a QTL influencing systolic blood pressure on 
chromosome 17 at 129 cM between markers D17S784 (77802182) and D17S928 
(80253028). When accounting for QTL-specific genotype-by-sex interaction, women 
showed and improved the LOD score of 3.3 for systolic blood pressure on chromosome 
17 at 136 cM [103].  
All these studies provide meaningful data in linking locations on the genome with 
a phenotype but the disadvantage of such a method is that the region between the two 
markers showing linkage is very large and it is assumed that every nucleotide in that 
region influences BP which may not be true. Another disadvantage is that the study 
linking a particular phenotype is very specific to the population it was studied on and 
is difficult to be replicated in another population.  
The 10th birthday of the human genome project was celebrated in April 2010 [104, 
105]. Technologic advances now permit the genotyping of hundreds of thousands to 
21 
 
more than a million SNPs on a single microarray at a reasonable cost that help to 
interrogate large proportions of the genome  [106, 107]. Association of these 
polymorphisms to GWAS  a disease trait like hypertension can help to obtain unbiased 
data of the genetic causes and hence can be considered a direct application of the human 
genome project (candidate gene analysis, linkage analysis) and HapMAP project which 
eventually leads to new methods of preventing, diagnosing, and treating diseases [105, 
108-110].  
 
Genome wide association studies (GWAS) - One of the first traits to be studied using 
GWAS is hypertension.  The first large collaborative study for hypertension, the Wellcome 
Trust case consortium (WTCC) reported the first GWAS results in 2007 [111]. The study 
consisted of 2000 cases and 3000 shared controls for 7 complex human diseases including 
hypertension. However none of the SNPs that was associated with BP were present on 
human chromosome 17 [111]. In a study done by Sabatti et. al., no genetic variants were 
found to be associated to blood pressure [112]. In 2009 Christopher Newton-Cheh et. al, 
formed the Global Blood Pressure Genetics (Global BPgen) consortium and conducted 
meta-analysis of GWAS in 34,433 individuals of European ancestry with SBP and DBP 
measurements followed by genotyping and in-silico analysis. The results of the joint 
analysis in up to 134,258 individuals of European ancestry along with reports obtained 
from the CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) 
consortium indicate genome wide significant associations for SBP at SNP id rs12946454 
on chromosome 17- 17q21 with the genes PLCD3 (Phospholipase C, Delta), ACBD4 
(Acyl-CoA binding domain containing 4), HEXIM, HEXIM2 (encoding Hexmethylene bis-
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acetamide inducible proteins 1 and 2) and FMNL1 (Formin-Like Protein 1) nearby, the 
SNP is in the intron of PLCD3 3 (Phospholipase C-delta isoform). The SNP, rs16948048 
associated with DBP at 17q21 is upstream of ZNF652 (zinc finger protein 652) and PHB 
(prohibitin) [113-115]. Neither gene was previously implicated in hypertension or other 
cardiovascular phenotypes. A follow up study of 133,661 additional individuals of 
European descent added GOSR2 (Golgi SNAP Receptor Complex Member 2) (SNP id 
rs17608766) as being associated with SBP. The SNP rs16960228 located in the gene 
encoding PRKCA (Protein kinase C, alpha), in chromosome 17q24.3 is found to be 
significantly associated with diastolic BP response to hydrochlorothiazide treatment in the 
[116]PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses Study) study 
of African Americans [117].  In a study published in 2014 by Franceschini et.al, three genes 
with multiple SNPS were marginally associated with SBP [TBC1D16 (TBC1 domain 
family, member 16), HRNBP3 (RAN Binding Protein 3) and AZI1 (5-azacytidine induced 
gene 1)] with AZI1 showing most prominence [118]. In a study published in 2014 by 
Simino et. al. using data from CHARGE, GBPgen, and ICBP from 99,241 individuals of 
European ancestry, they found two SNPs in the intron of NXN (Nucleoredoxin) gene 
(rs747685 and rs747687) that were associated with BP [119]. Recently Huan et al, 
conducted an association study of global gene expression levels in whole blood with BP 
traits (SBP, DBP, and hypertension) in six independent studies [116] . The study samples 
included: 3679 from the Framingham Heart Study (FHS), 972 from the Estonian Biobank 
(EGCUT), 604 from the Rotterdam Study (RS) [Division of Preventive Medicine, Brigham 
and Women's Hospital, 900 Commonwealth Avenue East, Boston MA 02215, USA], 597 
from the InCHIANTI Study, 565 from the Cooperative Health Research in the Region of 
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Augsburg [KORA F4] Study [Harvard Medical School, Boston, MA, USA], and 600 from 
the Study of Health in Pomerania (SHIP-TREND) [Icelandic Heart Association, 
Kopavogur, Iceland] totaling  7017 individuals. The results speculate that KCNJ2 
(Potassium Inwardly-Rectifying Channel) on HSA 17 may be important for BP regulation 
[116]. 
The findings of GWAS is promising in the field of blood pressure genetics and 
paves the way for subsequent investigations. Larger sample size can lead to greater power 
and help to find more variants involved in BP regulation. One major drawback of GWAS 
is that most of the published SNPs associated with diseases are not located in or near genes. 
They are located in regions where there are no annotated genes referred to as ‘gene deserts’. 
These regions previously referred to as ‘junk DNA’ are now known to be reservoirs for  
novel genes and regulators of distant genes. Another major drawback of GWAS is that the 
proportion of heritability explained by known variants indirectly assume that traits do not 
involve genetic interactions or epistasis and one can argue that high estimates of heritability 
have been misinterpreted. Such studies also do not give a clear answer to whether the 
variants are causal or only associated with the trait. The complexity of the complex traits 
is apparent from the range of factors that need to be considered as potentially contributing 
to the ‘missing heritability'. These can be rare variants whose significance is not yet 
recognized, less uncommon variants of small effect, or common variants of very small 
effect (very weakly penetrant) [120-125].  
 
Epistasis and Missing heritability- Complex traits or diseases can involve one or multiple 
genetic elements that work independently, additively or interactively with one another to 
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contribute to the trait. Such genetic interactions are known as epistasis. Epistasis can be 
defined biologically as well as statistically. Biologically, epistasis refers to gene-gene 
interaction where the action of a gene is modified by one or many other genetic elements. 
Statistically, epistasis can be defined as interaction between variants at multiple loci and 
the total effect that contributes to the trait is the combination of variants at the different loci 
and this effect may differ considerably from the effect of a linear combination of individual 
loci. This can help to indicate genetic loci that have a biological interaction [126-128]. One 
example of genetic interaction is the genetic heritability of obesity in family studies which 
in human familial studies is ∼40%, but in twin studies the number is higher (∼65%) [129, 
130]. This difference suggests that almost one-third of the heritable variance may be due 
to nonadditive genetic variance, including allelic and nonallelic gene interactions. In a 
study done by Dong et.al. the percentage fat mass analysis based on a two-locus epistatic 
model yielded significant evidence for interaction between chromosome 20q and the 
chromosome 10 centromere whose LOD score = 1.74; P=.024), compared with a two-
locus additive model whose LOD = 0.90. The results indicate that epistatic interactions 
between loci in these regions play a role in obesity [129].  
Candidate gene, Genome wide Linkage Studies, and GWAS are methods that have 
significantly increased our understanding of the genetic components underlying BP 
regulation. To complete the puzzle, focused studies considering epistasis, gene-
environment interactions, and rare variants in systematic and biologically ways are 
required and are underway.  Existing candidate gene and pathway studies can test epistasis 
and gene environment interactions using all available genotype and phenotype information 
even if no prior evidence linking them is available [131-135].  
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1.6 Animal models of hypertension and why the rat is a model of choice 
 
The genetic analysis of complex human traits like hypertension and blood pressure 
has been less successful than the genetic dissection of mendelian traits. Even the results 
obtained by linkage and association studies cannot be replicated consistently [136, 137]. 
This is usually due to effects of environment variability, genetic heterogeneity and 
incomplete penetrance of the disease [138]. Analytical approaches using animal models 
have the potential to overcome some of the genetic and environmental complexities of 
human studies. Researchers in the 1960’s and 1970’s developed genetic models of 
hypertension by selectively breeding rats and mice [139-154]. The first animal model of 
hypertension was made when Harry Goldblatt clipped the renal artery of a dog [155]. Rat 
and mouse have been used as models to study the genetics associated with disease traits 
but the rat has been the model of choice for many researchers because not many inbred 
mouse models of hypertension have yet been developed. Mouse is an animal of choice for 
gene knockout and overexpression transgenic studies and experimental manipulations of 
physiological systems are very informative on a physiological level because they provide 
information on how quantitative variation in candidate genes influences BP in the context 
of the whole animal with all its regulatory and compensatory systems intact [145]. Inspite 
of this the mouse does not make a good model for the discovery of naturally recombining 
genes that regulate blood pressure.  Mice are also not very useful in finding novel genetic 
variants or pathways that can lead to hypertension. The rat genome has approximately 2.75 
billion base pairs and the mouse has 2.6 billion base pairs compared to the human genome 
that contains 2.9 billion base pairs and the rat genome also contains almost all the 
corresponding genes known to be associated with diseases in human and are highly 
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conserved through evolution confirming that rat models are excellent for medical research 
[156, 157]. The larger size helps with ease of invasive measurements and mechanistic 
studies and better characterized physiology in rats also make it a suited model to study the 
trait of hypertension. Besides spontaneous hypertension is hard to occur in mouse hence 
the candidate genes for hypertension seem to be relevant more in rats and since the study 
on rats started early, various genetic models have been used to study the etiology of 
hypertension, most of them being rat models [145, 158-160].  
More than 50 years ago, Dahl et. al. selectively bred rats for sensitivity (S rats) and 
resistance (R rats) to study hypertensive effect of  a high salt (NaCl) diet [161]. This further 
helped to develop inbred strains of S and R rats from Dahl’s selectively bred lines and were 
the first rat models for studying salt-induced hypertension [162]. Other inbred strains used 
are the normotensive Lewis (LEW) rat, the spontaneously hypertensive rat (SHR), DOCA–
salt rats, Sabra hypertensive-prone rats, Milan, Lyon, fawn-hooded and Prague 
hypertensive rats [144, 163, 164]. These models provide a rapid and affordable way to 
identify and validate those novel candidate genes that play a role in the complex pathways 
that determine arterial pressure as predicted from human studies.  Recently rat transgenic 
technology has been well established and assemblies that link genotype to phenotype is 
available. All this information not only helps in the initial ascertainment of QTLs, but also 
in narrowing down the QTL regions of interest. Rats provide a rapid and affordable way to 
identify and validate novel candidate genes that are predicted from human studies to have 
a role in the complex pathways that determine arterial pressure [144, 145, 159, 165-170]. 
One example of a success story is the identification of a BP QTL on rat chromosome 10 
which is homologous to region on human chromosome 17 containing both a human QTL 
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[95], and the locus for Gordon's syndrome [33]. Variation in 11 β-hydroxylase gene in Dahl 
rats and similarly in human is also an example of quantitative variation in a steroid 
biosynthetic pathway causing an increase in BP [171-174]. 
Rodent studies have also shown that inspite of similar levels of increased BP, the 
susceptibility to end organ damage varies highly among different rodent strains. This 
implies that the phenotype of end organ damage is also genetically determined and 
identifying the causative genes can better our approach to risk assessment in human 
hypertension [175].  
 
Congenic substitution mapping  
 
Linkage analysis provides evidence for large chromosomal segments containing 
multiple genes and other regulatory determinants that influence BP. These segments are 
too large for positional cloning. As we now know, BP alteration may not be due to a single 
genetic determinant but could also be due to interactions and hence the region directly 
under the peak of the LOD plot may not always be a precise indication of the location [176, 
177]. Hence to shorten and resolve the large segment into smaller segments by natural 
recombination, congenic strains and substrains must be constructed [139, 178].  
Figure1-2 outlines the basic concept of making congenic models. It involves 
moving of genetic segments along with the polymorphic marker gene from one inbred 
(donor) strain (indicated in blue) to another inbred (recipient) strain (indicated in red).  The 
two strains are crossed, and the F1 heterozygotes are obtained. The F1 is then backcrossed 
to the recipient strain. The offspring will segregate to give a combination of homozygous 
and heterozygous strains in the ratio of 1 donor homozygous: 2 heterozygous: 
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1homozygous recipient. Heterozygotes are selected and backcrossed again to the recipient 
strain and the procedure is repeated for at least eight cycles of backcrossing and now the 
two offspring homozygous are bred to fix the donor allele on the recipient background. 
During each backcross, 50% of the genetic background becomes progressively enriched 
for the recipient strain genes until the background is 99% recipient genes after the eighth 
backcross. But the donor genes linked to locus we are trying to introgress will be pulled 
along and the resulting congenic strain will have only the locus of interest flanked by donor 
chromosomal segment [145, 179].  
The construction of congenic strains and backcrossing requires about 2.5–3 years 
of breeding to dilute out the unwanted donor genome outside the desired congenic region. 
The elimination of the donor genome can be expedited by selecting against donor strain 
alleles at markers strategically placed throughout the genome, at the same time one selects 
for donor alleles. This approach is also known as Marker Assisted Selection Protocols 
(MASPs) or speed congenic and utilizes genetic markers to facilitate the controlled 
introgression of genes within strains [180].  
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Figure 1-2 Diagram of the chromosomes as they appear in congenic strains 
constructed using the genomes of the normotensive LEW rat (blue) as a donor 
and a hypertensive S rat (red) as a recipient. The congenic genetic segment in 
the congenic strain is shown in blue.  This strain will have short segments of 
the LEW rat genome introgressed onto the genetic background of the S genome. 
(Picture courtesy Dr. Bina Joe) 
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Defining quantitative trait loci for blood pressure  
The genetic basis for variation in BP between different rat strains is hereditary and 
is passed down through generations but unlike Mendelian traits, the genotype based on 
change in BP does not yield any unique information about the genotype at any given single 
locus, because BP is the net effect across many loci. The existence of a QTL within a 
chromosomal region was initially detected using the candidate gene approach in 1972 using 
the biochemical genetic marker for steroid 11β- hydroxylase and later by restriction 
fragment length polymorphisms [181, 182]. Garrett et al did a study using F2 population 
derived from the Dahl salt sensitive S rat and normotensive LEW rats raised on 8% NaCl 
diet for 9 weeks and doing a systematic genome scan for BP QTL using 
MAPMAKER/QTL software. They found that congenic strains S.LEW(5) and S.LEW(10) 
made on chromosome 5 and 10 respectively yielded significant LOD scores (>3.5) [84, 
183].  This data is represented in Figure 1-3.  
The BP QTL on rat chromosome 10 is also reported on other F2 populations like 
F2(SxMNS) [184] and F2(SHRxWKY) [167, 185]. On RNO5,  the BP QTL was previously 
noted by Deng et al. [186] and a stroke QTL SHRSP and WKY is described in the similar 
location by Jeffs et al [187].   
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The software MAPMAKER/QTL can also be used to determine the existence of 
epistatic interactions making it especially beneficial for linkage analysis. An example is 
the detection of interacting loci in a double congenic strain on rat chromosomes 2 and 10 
[188].   
A similar interactive BP QTL was detected on RNO5 when the larger QTL obtained 
during linkage studies was dissected further by construction of a new iteration containing 
nine congenic substrains [189] demonstrating the presence of two closely linked BP QTLs. 
One of the QTLs was 6.3cM and another, 4.6 cM with a 1 cM distance between them. 
These substrains are shown in Figure 1-4a and b. The data implies that both the QTLs are 
closely linked and that neither one of the indicated QTLs when present alone gave a 
significant BP effect but when present adjoining each other cause a  significant BP 
lowering effect [189]. A hunt for the heritable transcriptional network regulated by the two 
interacting BP QTLs led researcher Lee et al to hypothesize that allelic interactions and 
transcriptional crosstalk between QTL 1 harboring gene Dmrta2 and QTL2 containing the 
gene Nfia are important for the BP lowering effect [190]. 
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Figure 1-4a Congenic strains for rat chromosome 5 with LEW as the donor strain on the S-rat genetic 
background. The linkage map is at the right, and the numbers denote map distances in centiorgans (cM). 
The solid bars to the left of the linkage map indicate the extent of the donor regions homozygous for the 
LEW alleles for each congenic strain. The open bars on the ends of these congenic segments indicate the 
interval in which recombination occurred. The effect on blood pressure of each strain compared with S 
rats is shown by the bar graph at the bottom. (n=20 per group); the standard error of this difference is 
indicated by the thin line at the end of the blood pressure bars. Significance levels by a t-test for the blood 
pressure effect are shown below each bar. A negative blood pressure deviation means that the congenic 
strain had a lower blood pressure than concomitantly studied S rats. The 2-LOD interval from our 
previous genome scan (10) is shown at the right. The LOD score peak is indicated by the solid diamond 
symbol and was 4.5. The deduced position of the blood pressure quantitative trait locus (QTL) based on 
the data from the congenic strains is indicated at the left, labeled “QTL 1.” *A linkage distance between 
markers D5Rat108 and D5Rjr1 could not be determined from the linkage panel because these markers 
are very close together.  
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Figure 1-4b Further derivation of congenic strains for rat chromosome 5. The 
format is the same as Fig. 1. Strains S.LEW(5)×6 and S.LEW(5)×5 are from Fig. 1. The 
other four strains were derived from S.LEW(5)×6 and are labeled S.LEW(5)×6×6, 
S.LEW(5)×6×9, S.LEW(5)×6×10, and S.LEW(5)×6×11. The data indicate the presence 
of two QTL (labeled “QTL 1” and “QTL 2”), both of which are required to retain the 
LEW allele in a given congenic strain in order for a significant blood pressure effect to 
be observed; the double-headed arrow between QTL 1 and QTL 2 is meant to imply this 
interaction. QTL 1 here is the same as QTL 1 in Fig. 1. See legend to Fig. 1-4a for 
description of the asterisk. 
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Chapter 2 
 
 
Materials and methods 
  
 
 
2.1 Rat strains 
Dahl Salt-sensitive (SS/Jr) inbred rats, designated as S, were from our colony 
maintained at the University of Toledo Health Science Campus. LEW/NCrlBR (LEW rats) 
were originally obtained from the Charles River Laboratories (Wilmington, MA) and 
maintained in our colony. All the animals were maintained and studied as per the 
institutional review committee’s approved protocol and IACUC protocols [191].  
 
2.2 Rat Diets 
The animals were maintained on a low salt (0.3% NaCl) diet from Harlan Teklad 
diet 7034 (Madison, WI). The rats that were used for experiments on high salt (2% NaCl) 
were given the Harlan Teklad diet TD94217. 
 
2.3 Genotyping 
Genomic DNA was extracted from rat tail biopsies using the Promega Wizard SV-
96, genomic DNA purification system. Primers were designed to amplify microsatellite 
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markers and SNP’s from genomic DNA sequences in the region of interest obtained from 
the rat genome data available and the Ensembl web site (www. ensembl.org). Polymorphic 
microsatellite markers were identified by PCR of genomic DNA and used for genotyping 
the congenic strains [192]. To narrow down the region of recombination, primers were 
designed around the SNPs and the genomic segment of S, LEW and congenic substrains 
were amplified using PCR. The PCR products were sequenced using the standard read 
sequencing service (http://www.operon.com/). 
 
2.4 Systolic Blood Pressure (SBP) measurement by the tail-cuff method 
Fifteen-20 male rats of each congenic strain were used for this study. Each congenic 
rat strain was bred, housed and studied concomitantly along with the control S rats. The 
animals were weaned at 30 days of age rats onto a low salt diet.  At 42 days of age the high 
salt group were switched to a 2% NaCl diet and the low salt group was maintained on the 
low salt diet for the duration of the experiment. Each cage contained one congenic and one 
S rat.  After 24-25 days on the respective diets, each rat had its systolic BP measured by 
two blinded operators. During BP measurements, rats were restrained and warmed to 28°C. 
The operators’ readings for each rat were averaged together and recorded as that animal’s 
systolic BP [193-195]. 
 
2.5 Corroboration of tail-cuff BP measurements by telemetry 
Rats from the tail-cuff study were continued on a 2% NaCl diet and surgically 
implanted with C40 radiotelemetry transmitters as described previously [191]. Telemetry 
was also done independent of the tail cuff method on younger rats (42do) by using the C10 
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transmitters and equipment from Data Sciences International [196]. The radio-telemetry 
transmitters (C-40 and C10) is implanted in anesthetized animals using 2% isoflurane. The 
cannula of the transmitter is inserted through the femoral artery and advanced to the lower 
abdominal aorta. The transmitter is inserted into the abdominal cavity. Once the procedure 
is completed, the animal is allowed to recover for a period of one week and continued on 
the 2% NaCl diet for the duration of the experiment. The blood pressure is then recorded 
continuously for 3 days.  
 
2.6 Urinary protein excretion 
Urinary protein excretion (UPE) was done by measurement of total protein in the 
urine over a 24 hour period after BP measurement was completed. The rats were caged 
individually in metabolic cages (Lab Products, Seaford, DE) with only water but no food. 
Urine was collected in measuring cylinders in the presence of 0.01% sodium azide and the 
total urine volume was recorded after 24 hours. The total protein level was determined by 
ready-to-use colorimetric method using Pyrogallol Red Molybdate dye binding mechanism 
(Quan Ttest red total protein assay system- Quantimetrix Corporation, Redondo Beach, 
CA). 
 
2.7 Genomic sequencing and analysis 
Primers are designed around the region to be sequenced (Integrated DNA 
Technologies Inc. (Coralville, IA). If large segments are involved, 1000kb overlapping 
regions are chosen. The PCR samples were sent to Eurofins MWG Operon (Huntsville, 
AL) for sequencing and the results were analyzed using the software Sequencher 4.9 (Gene 
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Codes Corporation). Once the RGD sequence variation data was publically available, the 
SNPs and INDELS were compared. 
 
2.8 Bioinformatics analysis 
 List of websites used:  
http://www.ncbi.nlm.nih.gov 
http://www.ensembl.org 
https://genome.ucsc.edu/ 
http://rgd.mcw.edu 
http://regrna2.mbc.nctu.edu.tw 
http://biotools.umassmed.edu/bioapps/primer3_www.cgi 
http://ihg.gsf.de/ihg/ExonPrimer.html 
http://www.genecards.org/ 
http://www.omim.org/ 
http://www.cbs.dtu.dk/services/Promoter 
https://cm.jefferson.edu/rna22/Interactive 
http://rnasoft-new.cs.ubc.ca/cgi-bin/RNAsoft/PairFold/pairfold.pl 
http://www.gwascentral.org 
 
2.9 RNA isolation and Real-time PCR 
Animals (S and congenic) were euthanized after a 2% NaCl diet after six weeks of 
age. The total RNA from kidney and heart were then prepared using RNeasy Mini Kit 
(Qiagen) and   TURBO DNA-freeTM Kit (Invitrogen) was used to remove the traces of 
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genomic DNA. Reverse transcription PCR (RT-PCR)was done using up to 5 ug of total 
RNA and reverse transcribed using Oligo-dT primers by using SuperScript® III First-
Strand Synthesis SuperMix (Invitrogen, Life Technologies,Grand Island, NY) to obtain 
cDNA. The cDNA concentration was measured by NanoDrop 2000 (Thermo Scientific). 
Real time PCR using Power SYBER® Green Mater Mix (Applied Biosystems, Foster City, 
CA) in the Step One Plus Real-time PCR System (Applied Biosystems) was performed 
using gene specific primers and 18sRNA was used as control. 
 
Promoter Assay 
Promoter function was determined by means of a luciferase reporter gene assay 
system (Promega Corp).   
Plasmid construction- The genomic region that was predicted by the software (Promoter 2.0 
prediction server) to contain promoter activity was PCR amplified using primers that 
flanked it. The total size of the construct was between 700-1000bp and constructs obtained 
from both, the S and LEW rats. The primers were designed such that it includes maximum 
number of polymorphisms in that region between S and LEW and contained the restriction 
sites for Nhe1 and Xho1. The fragment containing the predicted promoter segment was digested 
with Xho I and Nhe1 restriction enzymes and was then sub-cloned into the multiple cloning sites 
(Xho I and Nhe1) of pGL3-basic vector that lack eukaryotic promoter and enhancer sequences 
(Promega). The pGL-3 vector contains the cDNA encoded for firefly luciferase which when fused 
with a promoter, can be used to analyze the inserted promoter activity once transfected into 
mammalian HEK293T (Human Embryonic Kidney) cells.  All clones were verified by 
sequencing. Transfection was done using lipofectamine 2000 (Invitrogen Corporation, 
Carlsbad, CA, USA).  
40 
 
The vector encoded for the Renilla luciferase transcribed by a HSV-TK promoter 
was used as internal controls to normalize firefly luciferase expression. Forty-eight hours 
after transfection, the cells were lysed in passive lysis buffer (Promega). Cell lysate was 
added to the luciferase substrate (dual luciferase reporter system, Promega) and firefly and 
Renilla luciferase activity was measured with a luminometer (GloMax® 96 Microplate 
Luminometer w/Dual Injector).  
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Chapter 3 
Genetic determinants of blood pressure on rat 
chromosome 5 
 
 
 
Introduction 
 
Many blood pressure (BP) quantitative trait loci (QTLs) have been successfully 
located and fine mapped to short genomic segments spanning a few megabases or kilobases 
of the rat genome [176, 191, 196-205], (http://rgd. mcw.edu/). While some of the fine-
mapped QTLs act independently of each other, few BP QTLs have been identified as 
interacting or epistatic loci [188, 189, 206-218]. The work described here involves the 
study of two such QTLs on rat chromosome 5 (RNO5) that are closely linked and interact 
with each other to influence BP. The interacting QTLs, QTL1 and QTL2 linked to BP, 
were previously inferred based on differential segments between congenic strains 
constructed from the parental congenic strain S.LEW(5). These introgressed Lewis rat 
(LEW) segments were 6.3 and 4.6 cM on the genetic background of the Dahl salt sensitive 
(S) rat. Both these QTLs were captured in a single congenic strain S.LEW(5)x6x9 that was 
used as a parental strain for the current study [189, 190]. Isolating QTL1 and QTL2 as 
individual introgressed segments in two different monocongenic strains and reconstituting 
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them in a single bicongenic strain would provide direct evidence that LEW alleles within 
these two BP QTLs interact with each other to cause a BP lowering effect in the S rat. To 
obtain this important evidence, we generated a series of four different groups of congenic 
strains. Each group consisted of the following:  
1) One bicongenic strain containing introgressed LEW alleles on RNO5 at QTL1 and 
QTL2 separated by an S genomic segment,  
2) The two corresponding monocongenic strains, and 
3) The parental S strain.  
Each of these bicongenic strains were unique because they were developed by 
combining novel lines of monocongenic substrains containing introgressed LEW segments 
potentially different in their regions of recombination with the S genome. Data obtained 
from these new groups of congenic strains that is presented includes  
1) Definitive evidence for the presence of epistasis between the two closely linked 
QTLs,  
2) Capture of the two proposed epistatic QTL segments in independent congenic 
strains within better resolved intervals,  
3) Sequencing of the QTL regions, and 
4) Enlistment of potential candidate genetic elements. 
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Construction of the panel of monocongenic and bicongenic strains 
 
The bicongenic strains used for this study were derived from the parental strain 
S.LEW(5)x6x9 developed in our laboratory [190]. The parental strain S.LEW(5)x6x9 was 
bred with the S rat to generate an F1 population. The F1 rats were intercrossed to generate 
an F2 population.  F2 rats that had recombinations on RNO5 between the two microsatellite 
markers D5Mco39 and D5Mco47 were selected and backcrossed to the parental S strain to 
fix the recombination to homozygosity. Additional markers were used to determine the 
extent of the introgressed LEW alleles containing segments retained within each of the 
monocongenic strains. To develop bicongenic strains, male and female pairs of the 
monocongenic strains, each representing one of the two QTLs were randomly selected and 
intercrossed to develop F1 strains that were heterozygous at the two QTL regions. The 
animals containing the heterozygous alleles within each of the two QTLs were intercrossed 
to generate the bicongenic strains that were homozygous LEW at QTL1 and 2.  
 
Genomic sequencing and analysis  
 
Genomes of the SS/Jr and LEW/NCrlBR rat strains were sequenced on the next generation 
sequencing platform Illumina HiSeq2000 using paired end sequencing technology with 
100 bp read length and 350bp insert size. Sequence reads were mapped to the reference 
BN genome RGSC-3.4 [219] using short read aligner BWA-0.5.8c [220]. Genomic variants 
in SS/Jr and LEW/NCrlBR, relative to the BN reference genome, were identified using 
Genome Analysis Toolkit (GATK version 1.0.6001) [221] after rigorous pre-processing of 
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mapped reads including removal of clonal reads, indel realignment and base call 
recalibration. Potential false positives were filtered using variant quality score recalibration 
function of GATK which employs the Bayes Gaussian mixture model (GMM). Genomic 
variants (SNPs and indels) polymorphic between SS/Jr and LEW/NcrlBR in the two 
congenic intervals were then extracted using Perl script. Functional consequences of the 
SNPs and indels were estimated using Variant Effect Predictor (VEP) version 2.4 [222] on 
the Ensembl v66 rat gene set. All nonsynonymous variations in QTL 1 and 2 were 
independently validated with genomic DNA of S and S.LEW(5)x6Bx9x5 using primers 
designed to detect the variants by sequencing as described elsewhere[177] The list of 
primers used is provided in Table 3.1.  
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Table 3.1 List of primers for independent validation of nonsynonymous variations in 
protein- coding genes 
 
 
 
 
 
  
Gene 
name  
LEFT PRIMER  RIGHT PRIMER 
PROD
UCT 
SIZE 
Zcchc11 AGAATTCTCCCCAACCGTCT AGTCACCCAACCTTTCCACA 900 
Osbpl9 GCCACCATGCCTCATCTACT AAGAATGTGATGTGAGCCTTGA 601 
Raver2 CCCCTATGGGGGAAAGTAGA AAAGCCGATTGCATAAGGAC 840 
Zyg11a TCCCCCAGGACTGAGTTACA GAAAAGCTTCATGTGTGCTACAA 780 
Zyg11b 
GGAACTAAAAAGAAAAACCA
ACCA CCTTTTGCCACCACAAGCTA 780 
Faf1 TGCCCATGCCATGTAGATTA CCTCCTACACGTAGGCATCC 960 
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Results  
 
A panel of 12 congenic substrains including monocongenic and bicongenic strains 
were developed and assigned into four groups as shown in Figure 3-1.  Each group had a 
unique combination of LEW alleles within the two QTLs, QTL1 and QTL2 (Figure 3-1). 
Each group of animals was concomitantly raised along with the control S rats and their BP 
was measured using the tail cuff method (n=15-20 per group).  None of the strains in groups 
1, 2 or 3 differed in their BP compared to the S rat (Figure 3-1, Table 3.2).  However, 
within group 4, the SBP of the two monocongenic strains S.LEW(5)x6Bx9x5a and 
S.LEW(5)x6Bx9x5b were comparable to that of the S, but the bicongenic strain, 
S.LEW(5)x6Bx9x5 had a systolic BP of 157± 4.3 mmHg, which was 39 mmHg lower than 
the SBP of the S rat (SBP =196 ± 6.8 mmHg) (p < 0.001, Table 3.2).  Statistical analysis 
of the data obtained with the 3 strains in group 4 along with the S using two-way ANOVA 
showed significant interaction (p=0.041, Table 3.3). These data point to an interactive 
effect (labeled as ‘C’ in Figure 3-2).  The interactive effect was observed between the two 
introgressed segments within the monocongenic strains labeled as S.LEW(5)x6Bx9x5a and 
S.LEW(5)x6Bx9x5b in Figure 3-1. Further, because this interaction was not observed with 
any of the other groups of congenic rats, the introgressed segment contained within the 
strains S.LEW(5)x6Bx9x2a, S.LEW(5)x6Bx9x3a and S.LEW(5)x6Bx9x4a could be 
eliminated as BP QTL containing segments.  Therefore the most likely location of one of 
the interacting BP QTLs was interpreted to be within the 7.77 Mb orange-colored segment 
labeled as QTL1 in Figure 3-1.  The second orange-colored segment labeled as QTL2 in 
Figure 3-1 represents the BP  
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Figure 3-1 Schematic representation of the monocongenic and bicongenic strains developed- 
 Physical map of rat chromosome 5 (RNO5) along with the microsatellite markers, genes and their locations  
according to the Ensembl database (www.ensembl.com, RGSC 3.4) are shown in the left. The vertical bars 
alongside of the physical map represent schematics of congenic strains with black boxes representing  
introgressed Lewis segment and white boxes indicating S allele. The blood pressure effect is shown as black 
bars at the bottom of the congenic strains as measured by tail cuff method. BP data were analyzed by  
one-way ANOVA for each group. The blood pressure QTLs are indicated as orange bars at the right side.  
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Table 3.2 Blood Pressure effect of the four groups of monocongenic and their respective 
bicongenic strains by the tail-cuff method. 
 
 
 
 
 
  
Congenic substrain SBP (mmHg) ± SEM BP Effect(CONGENIC-S) p value 
S.LEW(5)x6Bx9x2 205 ± 5.1 0 1 
S.LEW(5)x6Bx9x2A 199 ± 4.2 -6 0.8 
S.LEW(5)x6Bx9x2B 204 ± 5.4 -1 1 
S 205 ± 3.4    
S.LEW(5)x6Bx9x3 226 ± 5.5 6 0.9 
S.LEW(5)x6Bx9x3A 221 ± 6.3 1 1 
S.LEW(5)x6Bx9x3B 231 ± 4.3  12 0.2 
S 220 ± 5.6    
S.LEW(5)x6Bx9x4 181 ± 2.5 -10 0.2 
S.LEW(5)x6Bx9x4A 184 ± 4.3 -7 0.5 
S.LEW(5)x6Bx9x4B 179 ± 3.2                     -12 0.06 
S 191 ± 2.1    
S.LEW(5)x6Bx9x5 157 ±  4.3 -39 <0.001 
S.LEW(5)x6Bx9x5A 190 ± 5.6 -6 0.9 
S.LEW(5)x6Bx9x5B 187 ± 5.2 -9 0.6 
S 196 ± 6.8    
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Table 3.3 Report of Statistical Analyses for Interactive Effects for Systolic BP measured 
by the Tail-cuff method by two-way ANOVA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Corrected Model 7624.999a 3 2541.666 9.718 .000 
Intercept 1037823.409 1 1037823.409 3967.973 .000 
QTL1 3584.586 1 3584.586 13.705 .001 
QTL2 2555.919 1 2555.919 9.772 .004 
QTL1 * QTL2 1199.786 1 1199.786 4.587 .041 
Error 7323.401 28 261.550   
Total 1082464.590 32    
Corrected Total 14948.400 31    
a. R Squared = .510 (Adjusted R Squared = .458) 
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Figure 3-2 Interactive Systolic BP effect. Results from group 4 are presented. The BP 
differences of the monocongenic strains compared to S rat are represented by intervals A and B. 
The additive BP effect expected in the bicongenic strain S.LEW(5)x6Bx9x5 is represented by 
the interval labeled A+B.  The difference between the expected and the observed BP of the 
congenic strain S.LEW(5)x6Bx9x5  is labeled as ‘interactive effect’ represented by the interval 
C. A two-way ANOVA showed that this interaction was significant, p=0.041 
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QTL that interacts with QTL1.  BP QTL2 spans 4.18 Mb, which is the introgressed LEW 
segment of S.LEW(5)x6Bx9x5b.   
To corroborate the result obtained by the tail-cuff method, the BP of 
S.LEW(5)x6Bx9x5a, S.LEW(5)x6Bx9x5b, S.LEW(5)x6Bx9x5 and S were additionally 
tested by the telemetry method (n=6/group for all strains except S.LEW(5)x6Bx9x5a, n=5). 
Similar to the data obtained by the tail-cuff method, the SBP of the two monocongenic 
strains S.LEW(5)x6Bx9x5a and S.LEW(5)x6Bx9x5b were not different from that of the S. 
However, the SBP of the bicongenic strain S.LEW(5)x6Bx9x5 was significantly lower than 
that of the S (p=0.041, Figure 3-3). Similarly, the diastolic blood pressure (DBP), mean 
arterial pressure (MAP) and pulse pressure (PP) of the bicongenic strain 
S.LEW(5)x6Bx9x5, but not either one of the monocongenic strains, were significantly 
lower than that of the S (DBP, p=0.036; MAP, p=0.009; PP, p=0.049; Figure 3-3). A two-
way ANOVA of the SBP, DBP, MAP, PP data obtained by the telemetry method further 
confirmed that the observed interaction was statistically significant in the bicongenic strain 
S.LEW(5)x6Bx9x5 (Table 3.4). 
Sequence variants within two identified QTL regions 
 
The location of the two QTL regions were queried by Blast searches of the 
sequences delimiting the two QTLs labeled as QTL1 and 2 in Figure 3-1. The genomic 
sizes of these QTLs differed between the rat genome assembly versions RGSC 3.4 and 
RGSC 5.0 (Table 3.5). The interpretations of genomic content of the two QTLs in the 
current report were based on RGSC 3.4 because this assembly was used to determine the 
sequences of the two QTL regions.  As per RGSC 3.4, QTL1 was located within 7.77 Mb 
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containing 85 annotations (Table 3.5) and QTL2 within 4.18 Mb containing 34 annotations.  
Genomic DNA sequencing of the QTL regions 1 and 2 identified 7360 and 2753 variants 
respectively, between S and LEW. These variant counts include single nucleotide 
polymorphisms and insertion and deletion polymorphisms. The majority of the variants in 
both the QTLs were outside of protein-coding genes. However, within QTL1, variants were 
confirmed in three protein-coding candidate genes (Table 3.6). These genes are Fas 
(TNFRSF6) associated factor 1 (Faf1) whose function is to potentiate FAS-induced 
apoptosis [223],  zyg-11 homolog A (Zyg11a) that probably acts as target recruitment 
subunit in an E3 ubiquitin ligase complex ZYGA-CUL2-elongin BC (By similarity) and 
zyg-11 homolog B (Zyg11b) is predicted as a target recruitment subunit in the E3 ubiquitin 
ligase complex ZYG11B-CUL2-Elongin BC [224] (Table 3.6). Similarly, within QTL2, 
one nonsynonymous variation and one splice-site variation was confirmed in the gene 
ribonucleoprotein, PTB-binding 2 (Raver2) that may bind single stranded nucleic acids 
(Potential) [225]. SIFT/PROVEAN (Protein Variation Effect Analyzer) software tool was 
used to analyze those variations in amino acids in genes that were confirmed to have non 
synonymous polymorphisms (http://sift.jcvi.org/). The results indicate a neutral effect due 
to the change in amino acid on the biological function of the protein coded by genes Zyg11b 
and Raver2. Given that the focus of the current study was to obtain definitive evidence for 
genetic interactions and localization of the two QTLs, constructing hypotheses around 
these candidate variants as the only potentially causative variants for the observed 
interactive effect is premature.  The congenic strains reported will serve as genetic tools 
for further fine-mapping and positional cloning of the two interacting loci. 
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Figure 3-3 BP effect of the QTL region detected by radiotelemetry- Radiotelemetry 
measures of systolic blood pressure, diastolic blood pressure, mean arterial pressure and 
pulse pressure of S and congenic strains (n=5-6). Rats were surgically implanted with large 
C40 radiotelemetry transmitters, allowed to recover for a week and BP was recorded over 
a period of 3 days. The data plotted is obtained by telemetry recording once every 5 min 
continuously and averaged for 4 hour intervals and is represented as Mean ± SEM  
Green: S.LEW(5)X6BX9X5; Black: S.LEW(5)X6BX9X5a; Blue: S.LEW(5)X6BX9X5b; 
Red : S 
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Table 3.4 Report of Statistical Analyses by two-way ANOVA for Systolic, Diastolic and 
Mean arterial blood pressure measured by the telemetry method 
(a) Dependent Variable: Systolic BP 
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 5036.072a 3 1678.691 4.912 .011 
Intercept 869142.857 1 869142.857 2543.049 .000 
QTL1 892.857 1 892.857 2.612 .123 
QTL2 845.873 1 845.873 2.475 .132 
QTL1 * QTL2 3200.635 1 3200.635 9.365 .006 
Error 6493.667 19 341.772   
Total 881431.000 23    
Corrected Total 11529.739 22    
a. R Squared = .437 (Adjusted R Squared = .348) 
 
 
(b) Dependent Variable: Diastolic BP 
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 10313.070a 3 3437.690 14.477 .000 
Intercept 479136.311 1 479136.311 2017.729 .000 
QTL1 88.406 1 88.406 .372 .549 
QTL2 3552.406 1 3552.406 14.960 .001 
QTL1 * QTL2 6185.200 1 6185.200 26.047 .000 
Error 4511.800 19 237.463   
Total 496372.000 23    
Corrected Total 14824.870 22    
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Table 3.4 Continued… 
  
(a) Dependent Variable: Mean arterial pressure 
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
      
Corrected Model 4070.713a 3 1356.904 5.159 .009 
Intercept 624046.959 1 624046.959 2372.707 .000 
QTL1 751.340 1 751.340 2.857 .107 
QTL2 760.102 1 760.102 2.890 .105 
QTL1 * QTL2 2472.229 1 2472.229 9.400 .006 
Error 4997.200 19 263.011   
Total 633594.000 23    
Corrected Total 9067.913 22    
a. R Squared = .449 (Adjusted R Squared = .362) 
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Table 3.5 Physical Sizes of the QTL intervals  
 
 
 
 
  
 RGSC 3.4 
Size of the QTLs 
(base pairs) 
RGSC 5.0 
Size of the QTLs 
(base pairs) 
QTL1 
124,085,611-
131,853,815 
7,768,204 
126,545,004-
134,002,747 
7,457,743 
QTL2 
117,894,038-
122,070,175 
4,176,137 
124,137,683-
124137683 
4,043,618 
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Table 3.6  List of single nucleotide polymorphisms within protein-coding genes 
 
 
  
GENE 
NAME POSITION 
SINGLE NUCLEOTIDE 
POLYMORPHISM 
(SNP)   S LEW BN LOCATION 
Faf1 131357775 
SNP- SPLICE SITE, 
INTRONIC A T T QTL1 
Zyg11a 129293730 
SNP- SPLICE SITE, 
INTRONIC T C T QTL1 
Zyg11b 129367632 
SNP-
NONSYNONYMOUS T C C QTL1 
Raver2 121784282 
SNP- SPLICE SITE, 
INTRONIC G A G QTL2 
Raver2 121786520 
SNP-
NONSYNONYMOUS C A C QTL2 
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DISCUSSION 
 
The locations of the interacting BP QTLs reported in this study were previously 
interpreted based on collective data obtained from several S.LEW congenic strains 
containing differential introgressed segments on RNO5 [189, 190].  Such interpretations, 
however logical, could be misleading without definitive evidence provided through the 
isolation and reconstitution of each of the two interacting BP QTLs [226].   Isolating 
interacting loci as introgressed segments within monocongenic strains and reconstituting 
these introgressed segments within bicongenic strains is relatively easier when the two 
interacting loci are on two different chromosomes. For example, two BP QTLs on 
chromosomes 2 and 10 are demonstrated to interact by the comparisons between two 
monocongenic strains with introgressed segments of chromosomes 2 and 10 and a 
bicongenic strain with both of the introgressed segments on chromosomes 2 and 10 [188]. 
Compared to this example, the present study was challenging because (1) the two epistatic 
loci were within a few megabases on the same chromosome and (2) the parental strain that 
was used for isolating the two interacting QTLs contains a contiguous LEW introgressed 
segment spanning the entire genomic segment from QTL1 through QTL2.  The study 
therefore required the replacement of the LEW segment between the locations of the two 
interacting loci with S alleles. This was achieved first by the construction of several 
monocongenic strains, followed by grouping these strains such that there were two 
monocongenic strains, one containing QTL1 and other containing QTL2. The two 
monocongenic strains within a group were used as progenitor strains for reconstitution into 
a bicongenic strain within the same group.  The data collected with four such groups of 
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monocongenic and bicongenic strains compared with the S clearly demonstrated that the 
two interacting BP QTLs were resolved as single introgressed segments within congenic 
strains that were 2.02 Mb apart. 
The sizes of the two QTL regions are amenable for further dissection using the 
congenic approach. QTL1 is homologous to two regions on human chromosome 1(HSA 1: 
50513686- 59012474 and 67390578- 67600639bp). QTL2 is homologous to chromosome 
1 in humans (HSA1: 61330931- 65697828 bp). Within these two regions there are no 
reported direct associations to blood pressure (http://www.genome.gov/gwastudies/). 
Genome-wide association studies (GWAS) do not  typically account for gene-gene 
interactions, whereby data on epistasis could be easily missed [123].  If similar epistasis, 
as described in our studies using rat models, does exist between the human homologous 
segments of QTLs 1 and 2, one would not expect current genome-wide association studies 
to demonstrate associations with either one of the homologous segments per se.   Indeed, 
there are no known associations to blood pressure within QTL2 on human chromosome 1. 
The current data thus points to epistasis, as described in our report, as perhaps contributing 
towards BP regulation by genetic elements within the homologous regions of QTLs 1 and 
2 in humans.  This, of course, remains to be determined.  
Genome-wide association studies of hypertension accounts for only about 1% of 
the inheritance of blood pressure. This observation is leading to recent literature pointing 
to epistasis as one of the factors contributing to ‘missing heritability’ of quantitative traits 
such as BP [220, 227]. The present study attests to epistasis as a possible factor contributing 
to ‘missing heritability’ in human hypertension GWAS because inheritance of a protective 
effect of LEW alleles at either QTL1 or QTL2 by itself did not result in an observable 
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change in BP. Therefore, the genomic segments could have been easily dismissed as ones 
that do not contain any genetic elements that causally alter BP. However, reconstitution of 
LEW alleles within QTL1 and QTL2 demonstrate that the ‘missing’ heritability is indeed 
accounted for by the presence of LEW alleles at both loci. Thus, results of rodent studies 
such as this, which are inherently more powerful in terms of their ability to dissect 
polygenic traits because of their ability for selective breeding schemata, points to epistatic 
effects in the molecular basis of hypertension in rodents. This may also contribute to the 
molecular basis of hypertension in humans and study designs that will detect such effects 
with the possibility that these will explain more of the heritability of human hypertension 
than has been possible with human hypertension GWAS to date. 
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Chapter 4 
Genetic determinants of blood pressure on rat 
chromosome 10 
 
 
 
4.1 Introduction 
 
 
The presence of blood pressure QTLs on rat chromosome 10 (RNO10) has been 
demonstrated previously by linkage analysis from our laboratory as well as other 
laboratories [167, 183-185, 206, 228-237]. Linkage mapping resulted in the identification 
of large genomic segments as being linked to BP and was located between markers 
D10Mit10 and D10Mco6 (~79-Mb). To dissect and refine this larger segment into smaller 
genomic segments, substitution mapping was applied in our laboratory. Accordingly 
congenic strains that encompass large regions of RNO10 were constructed by replacing the 
genomic suspect region of the hypertensive S rat with that of the normotensive LEW rats 
(S.LEW) [233].  One of the congenic strains used to study chromosome 10 is S.LEW(10) 
that contains the above mentioned ~79-Mb genetic segment that showed a significant 
lowering of BP by ~ 43 mm Hg compared with that of S [183, 233]. Using this congenic 
as a parental strain, further iterations of congenic substrains were constructed and the 
critical genomic segment was further resolved. Along with other congenic substrains in the 
iteration, S.LEW(10)x12 showed a significant lowering of BP of 25 mm Hg compared to 
S. A similar study had been previously done on a 32-cM segment from MNS rats 
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introgressed into the S genetic background which also showed a BP-lowering effect of 34 
mm Hg compared with S [230]. In humans, a sib pair analysis by Julier et al found 
significant linkage of BP to markers in the region of HSA17 that was homologous to the 
BP QTL region of RNO10 obtained by linkage analysis [95] which was later confirmed by 
Baima et al [238].  
Fine mapping of the congenic segment on rat strain S.LEW(10)x12 was important 
to locate Quantitative trait nucleotides (QTNs) or Quantitative trait genes (QTGs) that are 
functional in regulating BP. After making a new iteration of congenic substrains and based 
on differential congenic segmentation, the QTL on RNO10 was further resolved and 
mapped to a 1.17Mb (shown by the orange bars labelled as S.LEW BP QTL in Figure 4.1) 
on substrain S.LEW(10)x12x2x3 which had a 2.35 Mb LEW segment. This region contains 
18 genes and homology mapping indicates that the 1.17-Mb BP QTL in 
S.LEW(10)x12x2x3 is not within any of the BP regulating regions mapped in human 
showing significant linkage. However, the region is also a candidate region for human 
familial hyperkalemia and hypertension (pseudohypoaldosteronism type II, Gordon’s 
syndrome) [239].  This may suggest that there are perhaps many genetic factors influencing 
BP that are yet to be discovered in humans [191]. The alternate possibility is that rats and 
humans do not share this location as BP QTLs.  
During phenotyping of any congenic strain, the net effect of alleles is what is 
measured but the underlying contributing factors to the observed net effect remains 
unknown. Hence mapping using congenic intervals as QTL is more appropriate than 
mapping by differential segments as QTL intervals. Differential segmentation is effective 
in hypothesis generation but requires further validation using congenic strains. Hence  to 
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locate the genetic determinants of BP within congenic strains with shorter introgressed 
segments, a new iteration of substrains was made from the parental S.LEW(10)x12x2x3 
congenic that had an introgressed LEW segment of 2.35 Mb encompassing the entire 1.17 
Mb BP QTL [192]. However this genetic segment is not directly under the apex of the LOD 
plot suggesting that we may miss the underlying genetic determinants of BP if we fixate 
on those genes that are close to the point of the highest statistical evidence in a linkage 
study. One of the congenic substrains obtained from the parental S.LEWx12x2x3 is 
S.LEW(10)x12x2x3x8 (1.3Mb LEW segment) showed a significant BP lowering effect. 
Another substrain S.LEW(10)x12x2x3x5 (375kb LEW segment) showed a significant 
increasing BP effect compared to S rat. This helped to divide the 1.3Mb segment on 
S.LEW(10)x12x2x3x8 into multiple regions- region1 (401kb), region2 (104kb) and 
region3 (409kb). This is represented in Figure 4-1.  
 In an attempt to study the strain S.LEWx12x2x3x5 containing the 104kb LEW 
segment (region 2) that led to a further increase in BP of the S rat, SNP genotyping was 
conducted to resolve the region of recombination and the QTL was resolved to a <42.5kb 
between the base pairs 71028112 and 71070581 and this critical (<42.5kb) region 
contained a single predicted gene, Rififylin (Rffl) with no exonic variants [196, 240]. This 
gene was prioritized as a candidate gene in BP regulation. 
The aim of the current study is to fine map these three regions and resolve them to 
the highest possible extent. The strain S.LEW(10)x12x2x3x8 spanning a 1.34Mb LEW 
introgressed segment containing all the three regions, region 1 (401 kb), region 2 (<42.5 
kb) and region 3 (409 kb) was chosen as a parental strain to make future congenic 
substrains and conduct fine mapping studies to refine the three regions. 
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Figure 4-1 Congenic substrains and their phenotypic effects. The relevant section of the 
physical map of RNO10 is shown to the left of the Figure. Values in parenthesis next to the marker 
names indicate their physical locations in base pairs. The previously mapped BP QTL1 region is 
shown as the orange bar flanked by 2 open arrows. Congenic strains are shown as solid colored 
bars flanked by open bars. Solid color bars illustrate the LEW segment introgressed onto the 
background of S. The open bars at the end of each introgressed segment represent the region of 
recombination. Green colored bars represent the LEW introgressed segment in congenic 
substrains with a BP effect, whereas the dark gray colored bars represent the congenic substrains 
without a BP effect. The locations of the newly determined BP Regions 1, 2, and 3 are presented 
at the right of the illustration as orange, peach, and blue bars. The bottom portion of the Figure 
illustrates the BP and HW effect observed for each congenic substrain compared with that of the 
S rat BP: Green bars represent a significant BP effect, black bars represent a BP effect with a 
probability value <0.05, hatched bars represent a significant HW effect, and open bars represent 
a HW effect with a probability value <0.05. 
Adapted with permission from Saad et. al. Hypertension 2007;50;891-898 
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4.2 HYPOTHESIS 
 
 
Genetic determinants within the three regions (region 1, region 2, and region 3) regulate 
blood pressure. 
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4.3 Construction of congenic strains- The original congenic strains 
S.LEW(10)X12X2X3X8 and S.LEW(10)X12X2X3X5 (shown in Figure 4.1) and congenic 
substrains were constructed in our laboratory and maintained in the animal facility.  These 
two strains were used as the progenitors and were backcrossed with S rats to obtain an F1 
generation and this F1 generation was intercrossed to produce a F2 population. The rats 
with recombinations within the congenic segment were crossed with S to duplicate the 
recombinant chromosome and then selectively bred to fix the recombinant chromosome to 
homozygosity on the S background [233]. 
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4.4 Results 
4.4.1 High resolution mapping of BP QTL on S.LEW(10)x12x2x3x8 (region 1 and 
3) 
 
The F2 rats obtained from the parental S.LEW(10)x12x2x3x8xS (Figure 4-1) 
population were screened for polymorphism using the microsatellite markers D10Mco83 
and D10Mco62 (Table A.1).  Two recombinant progeny obtained were backcrossed to the 
S to fix for homozygosity. The resultant congenics were named as 
S.LEW(10)x12x2x3x8x1 (C1) and S.LEW(10)x12x2x3x8x2 (C2) and contained a 
893.76kb and 435.5kb respectively of introgressed LEW alleles (Figure 4-2) .  Systolic BP 
(SBP) of male rats on a high salt diet for 21 days belonging to the two strains along with 
concomitantly raised S rats were measured by the tail cuff method (Figure 4-3) and 
survival, final body weight (FBW), relative heart weight (RHW) and total kidney weight 
(TKW) was also recorded (Table 4.1). As seen in Figure 4-3, C1 showed a significant BP 
decreasing effect of -27 ± 8.6 mmHg (p=0.0041) whereas C2 showed no BP effect (-4 ± 
10 mmHg, p=0.7) compared to the S rat. As seen in Table 4.1, RHW of only C1 was 
significantly lower than that of S (0.2 ± 0.05gms, p=0.0013) but this effect was not seen in 
case of C2 (0.1 ± 0.06gms, p=0.06). The final body weight effect of C1 and C2 were not 
significantly different from that of S (11.5 ± 6 gm, p= 0.07 and 12.7 ± 9 gm, p=0.2 
respectively), and total kidney weight of congenic 1 (0.09 ± 0.1 gm, p= 0.4) and C2 (0.10 
± 0.1 gm, p= 0.3) strains were also not significantly different from that of the S. The 
survival of these animals as measured by the Kaplan Meier plot shows that the lifespan of 
the C1 is significantly higher than the S rat (p<0.001) on high salt but C2 showed no such 
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effect (p=0.54) (Figure 4-3). Urinary protein excretion of these two strains was not 
measured. 
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Figure 4-2 New iteration of congenic substrains. The black bar on the left side shows the relevant 
section of the physical map of RNO10. The left side of this bar has the names of the polymorphic end 
markers and the SNPs in the form of (S/LEW) and the right side of the bar has the physical location of 
these markers and SNPs in base pairs. The bars in orange on left side are the previously mapped QTLs 
and the current QTLs are given at the right end. Congenic strains are shown as solid colored bars flanked 
by open bars. Solid color bars illustrate the LEW segment introgressed onto the background of S. The 
open bars at the end of each introgressed segment represent the region of recombination. Green colored 
bars represent the LEW introgressed segment in congenic substrains with a BP effect, whereas the black 
colored bars represent the LEW introgressed segment in congenic substrains without a BP effect. At the 
bottom is the BP effect of the corresponding strains above.  
70 
 
  
 
T
a
b
le 
4
.1
 
P
h
en
o
ty
p
ic 
ch
a
ra
cteriza
tio
n
 
o
f 
co
n
g
en
ic 
su
b
stra
in
s- U
rin
ary
 p
ro
tein
 
ex
cretio
n
 (U
P
E
), 
relativ
e h
eart w
eig
h
t (R
H
W
), to
tal k
id
n
ey
 w
eig
h
t (T
K
W
-left +
 rig
h
t k
id
n
ey
 w
eig
h
t) an
d
 fin
al b
o
d
y
 w
eig
h
t 
(F
B
W
) w
as reco
rd
ed
 at th
e en
d
 o
f th
e B
P
 stu
d
y
. T
h
e sig
n
ifican
t v
alu
es (p
<
0
.0
5
) are in
d
icated
 b
y
 *
 
 
 
U
P
E
/k
g
 b
w
t/2
4
h
rs 
R
H
W
 (g
) 
 
S
 
C
O
N
G
E
N
IC
 
E
F
F
E
C
T
 
p
 V
A
L
U
E
 
S
 
C
O
N
G
E
N
IC
 
E
F
F
E
C
T
 
p
 V
A
L
U
E
 
C
1
 
- 
- 
- 
- 
5
±
0
.3
 
4
.5
±
0
.0
9
 
-0
.5
 
0
.0
4
8
*
 
C
2
 
- 
- 
- 
- 
5
±
0
.3
 
4
.5
±
0
.3
 
-0
.5
 
0
.1
8
 
C
3
 
2
1
6
.2
 ±
1
3
 
2
3
2
.8
 ±
 1
4
 
1
6
.5
2
 
0
.4
0
 
3
.8
 ±
 0
.1
 
3
.9
 ±
 0
.1
 
0
.0
9
 
0
.5
6
 
C
4
 
2
6
2
.7
 ±
 2
4
 
2
4
3
.5
 ±
 2
2
 
-1
9
.2
0
 
0
.6
0
 
4
.1
 ±
 0
.1
 
4
.2
 ±
 0
.1
 
0
.0
8
 
0
.6
0
 
C
5
 
2
4
6
.6
 ±
 2
6
 
2
3
3
.8
 ±
 2
6
 
-1
2
.8
0
 
0
.7
3
 
4
.9
 ±
 0
.3
 
4
.7
 ±
 0
.2
 
-0
.2
0
 
0
.5
4
 
C
6
 
2
2
7
.6
 ±
 1
3
 
2
5
2
.5
 ±
 1
7
 
2
5
.0
0
 
0
.2
7
 
3
.8
 ±
 0
.1
 
4
.1
 ±
 0
.1
 
0
.3
0
 
0
.0
4
*
 
C
7
 
2
4
9
.0
 ±
 2
0
 
1
8
3
.6
 ±
 7
 
-6
5
.4
1
 
0
.0
0
6
*
 
5
.1
 ±
 0
.2
 
3
.8
 ±
 0
.2
 
-1
.2
2
 
<
0
.0
0
1
*
 
 
 
 
 
 
 
 
 
 
 
T
K
W
 (g
) 
F
B
W
 (g
) 
 
S
 
C
O
N
G
E
N
IC
 
E
F
F
E
C
T
 
p
 V
A
L
U
E
 
S
 
C
O
N
G
E
N
IC
 
E
F
F
E
C
T
 
p
 V
A
L
U
E
 
C
1
 
4
.0
1
±
0
.0
 
4
±
0
.0
 
-0
.0
1
 
0
.3
5
 
3
1
9
±
7
 
3
0
8
±
2
 
-1
1
 
0
.0
7
 
C
2
 
4
.0
1
±
0
.0
 
4
±
0
.0
6
 
-0
.0
1
 
0
.3
7
 
3
1
9
±
7
 
3
0
7
±
7
 
-1
2
 
0
.1
7
 
C
3
 
1
.8
 ±
 0
.0
4
 
1
.6
 ±
 0
.1
 
-0
.1
5
 
0
.0
4
*
 
3
1
7
 ±
 6
 
3
0
8
 ±
 6
 
-9
.7
 
0
.3
 
C
4
 
1
.8
 ±
 0
.1
 
1
.7
 ±
 0
.0
4
 
-0
.0
4
 
0
.5
3
 
2
9
3
 ±
 6
 
2
9
7
 ±
 5
 
4
.6
 
0
.6
 
C
5
 
2
.2
 ±
 0
.1
 
2
.1
 ±
 0
.2
 
-0
.1
0
 
0
.7
0
 
3
4
1
 ±
 1
6
 
3
5
3
 ±
1
9
 
1
1
.9
 
0
.7
 
C
6
 
1
.8
 ±
 0
.0
4
 
1
.9
 ±
 0
.1
 
0
.1
8
 
0
.0
4
*
 
3
1
5
 ±
 4
 
3
0
2
 ±
 6
 
-1
2
.1
 
0
.1
 
C
7
 
2
.1
 ±
 2
.2
 
2
.1
 ±
 0
.2
 
-0
.0
2
 
0
.7
0
 
3
4
3
 ±
1
3
 
3
8
3
 ±
1
2
 
3
9
.2
 
0
.0
4
*
 
 
71 
 
 
 
 
 
Figure 4-3 Systolic blood pressure and the Kaplan-Meier survival plots for C1 and 
C2.  
The black bar indicates SPB (mmHg) of the S, Grey bar indicates the SBP of strain C1 
and white bar represents SBP of C2 
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Figure 4-3 Systolic blood pressure and the Kaplan-Meier survival plots for C1 and 
C2.  
Top- Systolic blood pressure of male rats on 2% NaCl diet was measured using tail cuff 
method. Error bars (SEM) are indicated on top of each bar and * indicates significant 
difference. (n=15-20 per group) the SBP values are S= 213.4±7.1 mmHg,                 
C1= 186.6±5.2mmHg, C2= 217.5±6.4mmHg. The y axis represents the SBP in mmHg 
and the x axis represents the strains. The black bar is S, grey bar is C1 and white bar is 
C2 
Bottom- The survival study for S1 (n=14) was done along with C1 (n=15) and S2 
(n=14) was done along with C2 (n=16). These animals were continued on high salt (2% 
NaCl) after the BP experiment until their natural death. S1 versus C1, p=0.0009 and S2 
versus C2, p=0.51 
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The two strains, congenic 1 and 2 (C1 and C2) were then used as parental strains to further 
narrow region 1, 2 and 3 by making a new iteration of congenic substrains. The four new 
congenic substrains obtained are- S.LEW(10)x12x2x3x8x1x1 (C3), 
S.LEW(10)x12x2x3x8x1x2 (C4), S.LEW(10)x12x2x3x8x2x3 (C5), and 
S.LEW(10)x12x2x3x8x2x4 (C6) (Figure 4-2). BP by telemetry method was measured and 
urinary protein excretion was studied as a unit of renal function. RHW, TKW and FBW 
was noted after the experiment was completed.  
 The LEW introgressed segment for C3 is 752.4kb (71169252bp to 71921657bp) 
and C4 is 517.08kb (71545930bp to 72063014bp). The region of recombination was 
genotyped using SNP data for S and LEW rat genome on 
http://rgd.mcw.edu/rgdweb/front/select.html and hence SNP locations along with 
microsatellite marker locations have been indicated in the figure (Figure 4-2). C3   did not 
show a significant SBP effect at any time point during the three day course of BP 
measurement (Figure 4-3a) but C4 had significantly lower SBP at every time point 
compared to the S rat during the three days of BP measurement with the effect ranging 
from -13 to -20 mmHg (Figure 4-4b). The UPE effect of C3 (p=0.4) or C4 (p=0.6) did not 
differ significantly compared to the S rats. (Table 4.1).   
C5 has an introgressed LEW segment of 49.4kb and spans across the region 
70752452bp to 70801867bp. (Figure 4-2). The strain shows no significant change in SBP 
or DBP compared to the S rat at any time point during the three days that the telemetry 
recordings were monitored but MAP showed significant lowering at all time points. 
(Figure4-4c) There was also no significant change in the UPE, RHW, FBW or TKW as 
compared to the S rat (Table 4.1).   
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C6 has an introgressed LEW segment between 70878449bp and 71170090bp 
(291.64kb). The alleles in the LEW segment causes a significant increase in BP of the S 
rat (Figure 4-4d). The RHW (p=0.04) and TKW (p=0.04) is significantly higher that the S 
rat strain but there is no change in the UPE (p=0.27) and FBW (p=0.1) measured on high 
salt diet compared to S (Table 4.1).   
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Figure 4-4 Radiotelemetry data for C3, C4, C5 and C6. Data plotted shows the 
recording obtained once every 5 minutes over a period of three days and the data points 
plotted are averaged for 4 hour intervals. The p values are obtained by 1-way ANOVA 
followed by Tukey- HSD test. Error bars represent the standard error of the mean. The 
values obtained from the S rat are plotted in red and the values from the congenic are 
plotted in green. The black bars on the x axis indicate the night cycles.  
Figure 4-4a BP data for S (n=11) and C3 (n=10). The data points are not significantly 
different at any time point (p>0.05).  
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Figure 4-4b BP data for S (n=10) and C4 (n=11). The data points that are not significant 
(p>0.05 is indicated in #) and if the data points are not significant except at few points 
they are marked by *.  
 
 
p>0.05 at all points 
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Figure 4-4c BP data for S (n=6) and C5 (n=8). The data is not significantly different at 
any time point except for mean arterial pressure where p<0.05 at all points. 
 
 
p>0.05 at all points p>0.05 at all points 
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Figure 4-4d BP data for S (n=11) and C4 (n=10). The data points are not significant 
except at few points that are marked by *.  
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Discussion 
  
The three regions (region 1, 2 and 3) mapped previously on the parental strain 
S.LEW(10)x12x2x3x8 containing a LEW segment of 1.34Mb is now divided between the 
two substrains  S.LEW(10)x12x2x3x8x1 containing a LEW segment of 902.26kb and 
S.LEW(10)x12x2x3x8x2 containing a  435.5kb LEW segment.  
The substrain C1 shows a significant BP lowering effect and significant reduction 
in relative heart weight. This could indicate that the LEW alleles responsible for lowering 
of BP of the S rat could also be involved in protection of the heart against hypertrophy 
[145, 241-243]. The LEW introgressed within the strain spans across the genomic location 
71160976bp to 72063232bp and contains the entire region1 (71662574bp to 72063232bp) 
and part of region 3 (71160976bp to 71476900bp).  
The substrain C2 (LEW segment lies within genomic location 70725437bp to 
71160976bp), showed no BP effect even though it contains the previously reported strain 
S.LEW(10)x12x2x3x5 (<320.6 kb) in its entirety which exhibited a significant BP 
increasing effect (Figure 4-2). The substrain contains all of region 2 (70996834bp to 
71100513bp) and part of region 3 (71067496bp to 71160976bp). This may be evidence 
that C2 contains genetic elements within the QTL that are interacting with each other to 
mask out or cancel the BP increasing effect when additional LEW alleles in the location 
71067496bp to 71160976bp are present along with the LEW segment in the 
S.LEW(10)x12x2x3x5 strain.  
This helps to strengthen the hypothesis that the previously prioritized gene Rffl  
[196, 240] is a genetic factor involved in BP regulation.   
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Strain C3 contains part of region 1 (71662574bp-71921657bp) and region 3 
(71169252bp-71476900bp). This strain showed no BP effect and no UPE, RHW or FBW 
effect compared to S rat strain indicating that the LEW alleles in the integrated segment 
may not independently regulate BP. Strain C4 has a significantly lower SBP, DBP and 
MAP compared to S strain. Measurement of heart beat per minute shows significantly 
higher heart rate during the active night cycles in this strain which may indicate a better 
heart function compared to the S rats. The LEW introgressed segment in this congenic 
strain contains the entire region1. By differential segmentation using C3 and C4, the region 
1 (401 kb) can be fine mapped to a 141kb BP QTL that contains BP regulating elements.  
This shorter region 1 contains three protein coding genes- Heat repeat containing protein 6 
(Heatr6) which has been implicated in breast cancer in human [244] studies, Extracellular 
proteinase inhibitor (Expi), and LOC360228 each of which are potential candidates for BP 
regulation. Previously it was reported that Expi did not show any variations between S and 
LEW [191]but the gene showed a significant change in expression in the kidney samples 
(2.71 times higher in S). LOC360228 showed significant change in expression in heart 
samples (3.6 times higher in S compared to parental S.LEWx12x2x3x8) [192].  
Strain C5 did not show any BP effect or changes in the other measured phenotypes 
measured whereas strain C6 containing part of region3(71070581bp-71170090bp) and the 
entire region 2 showed a BP increasing effect further strengthening the hypothesis that  Rffl 
may be an important factor in BP regulation. With the help of C3 and C6, region 3 has also 
been refined by congenic differential segmentation to a smaller 103 kb region containing 
4 protein coding genes- DNA repair protein RAD51 homolog 4 (Rad51l3), Fibronectin 
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Type III Domain Containing 8 (Fndc8), Notchless Homolog 1 (Nle1), Unc-45 Homolog B 
(Unc45b).  
  
82 
 
4.4.2 High resolution mapping of BP QTL on S.LEW(10)x12x2x3x5 (region 2) 
 
 
 
 
The strain S.LEW(10)x12x2x3x5 containing region 2 was previously reported to 
show a BP increasing effect compared to the hypertensive S rat and the gene Rffl was 
prioritized as a candidate in BP regulation [196, 240]. To confirm the role of Rffl gene, we 
attempted to make substrains containing shorter congenic segments that have only the Rffl 
gene. Before I started my dissertation work in the laboratory, several rounds of breeding, 
genotyping to screen for recombinants was carried out on approximately 2000 animals but 
the parental strain S.LEW(10)x12x2x3x5  did not produce any sub-strains that recombined 
to include the LEW alleles at region 2  containing the Rffl gene. But the process of natural 
recombination yielded a congenic substrain S.LEW(10)x12x2x3x5x1 (C7) (Figure 4-2) . 
Hence we phenotyped this strain to help us fine map the LEW segment on the parental 
S.LEW(10)x12x2x3x5.  
C7 spans the genomic region 70752452bp to 70868736bp (116.3kb). Using the 
tailcuff method, SBP of male rats on high salt was measured.  The C7 strain has 
significantly lower SBP (183.4 ± 4 mmHg) compared to the S rat (211.5 ± 6 mmHg) with 
a SBP effect of -28 mmHg, p<0.001 (Figure 4-5). To determine if the alleles responsible 
for the BP lowering effect is salt sensitive, SBP of male rats was again measured using the 
tailcuff method on a high (2% NaCl) and low (0.3% NaCl) salt diet. The results 
demonstrate that the BP lowering effect was observed only when the animals were on a 
high salt diet (SBP effect= -28 mmHg, p=0.001) and not on a low salt diet (SBP effect=  
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-6 mmHg, p=0.2) (Figure 4-5).  Further a similar experiment was done on female rats to 
determine if the BP lowering effect was gender specific. The results demonstrated that SBP 
of female C7 rats also showed a significant BP lowering effect of -19mmHg, p=0.001 (C7= 
167.3 ± 3mmHg and S= 186.1 ± 4mmHg) on a high salt diet but no BP effect was noted 
on a low salt diet (C7 was 171.7 ± 3mmHg and S was 172.5 ± 3mmHg, p=0.8) (Figure 4-
5).  
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Figure 4-5 SBP data obtained by tail cuff method for C7. Error bars represent the standard error 
of the mean. The BP effect that are significant (p<0.05) is indicated in *.  
Top- BP data for S (red) and C7 (green) males. (On 2% NaCl (S=18 and C7 =20) and 0.3% NaCl (S= 
13 and C7 =13). 
Bottom- BP data for S (red) and C7 (green) females. (On 2% NaCl  S=13, C7=13) and 0.3% NaCl 
S= 16 and C7=18). 
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As seen in Figure 4-6, the urinary protein excretion of both male and female C7 rats were 
significantly lower compared to the S strain following a high salt diet. The UPE effect of 
the male C7 strain was -65.41/kg bwt/24hrs (p=0.006) (male C7=249.0 ± 20/kg bwt/24hrs 
and S rat was 183.6 ± 7/kg bwt/24hrs) and the female C7 showed a UPE lowering effect of  
-46.48 ± 21/kg bwt/24hrs (p=0.04) (C7female= 225.3 ± 10/kg bwt/24hrs and S female rat 
(271.7 ± 19/kg bwt/24hrs) on a high salt diet. A similar UPE lowering effect was not 
observed on a low salt diet. Figure 4-6 also shows that the survival of the male C7 animals 
on high salt as represented by the Kaplan Meier plot is also significantly higher (p=0.0023) 
than the S rats with a median survival of 145.5 days for C7 and 110 days for the S rats. 
There was a significant lowering of relative heart weight of C7 male rats on high 
salt diet by -1.222 ± 0.2 g (p= < 0.001) compared to that of the S rat (Table 4.1). This effect 
was not observed in the total kidney weight (p= 0.73).  
The SBP results obtained by tail cuff method was corroborated using the telemetry 
method at 68 days of age and the results are shown in Figure 4-7. The results obtained from 
a three day BP period recording indicate that at every data point plotted, there is a 
significant decrease of SBP and DBP of the C7 compared to the S rat ranging from -26 
mmHg to -38 mmHg. DBP lowering effect was also significant and ranged from -18 to -
27 mmHg.  
To determine the age at which the protection from high BP on high salt starts, BP 
measurements were monitored on 42 days old rats using by C10 radiotelemetry probes. 
Even at young age of 42 days, SBP of the C7 rats were significantly lower than the S rat 
(Figure 4-7).  
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On high salt 
Figure 4-6 Urinary Protein Excretion and Kaplan Meier plot for C7. 
Top- UPE of male and female congenic substrain C7 (green) was compared to the S rat strain (red). 
SEM is plotted on the bar graphs and * indicates significant effect where p<0.05. n =15-17. 
Bottom- Kaplan- Meier curves- Animals from both groups, C7 and S (n=10-12) were fed with 0.3% 
dietary salt for 6 weeks and then fed with 2% NaCl until their natural death. (P= 0.0023).  
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Figure 4-7 Radiotelemetry data for C7. 
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Figure 4-7 Radiotelemetry data for C7.  
Top panel- C40 probes were used on 63 day old S rats (red) and C7 (green) animals and 
the data plotted is obtained by taking a 4 hour moving average of telemetry recording 
obtained every 5 minutes continuously over a period of 3 days. N= 12 per group. The 
black rectangles indicate the night cycle in a 24 hour time frame 
Bottom panel- Early time point assessment of BP by telemetry method was done in 
younger animals (42do) S-red and C7 (green) by implanting them with the C10 probes.  
Data is collected every 5 minutes for one day and plotted using the 4 hour moving 
average.  
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To find which SNPs/INDELS may be candidates for the change in BP, the genomic 
sequencing of the introgressed LEW segment of congenic 7 strain was completed using the 
standard read sequencing services by eurofinsgenomics.com before the genomic sequence 
of the SS/JR (ICL) and LEW/NCrl (ICL) was published [245].  Data obtained from RGD 
(http://rgd.mcw.edu) indicated that the LEW segment between positions 70752452 to 
70868736 has a total of 174 SNPs. According to the genomic sequencing done by our lab 
the LEW segment has a total of 224 SNPs and 50 INDELS (Table 4.2).  
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Position (RGSC 3.4) 
TOTAL SNPs/INDELS 
RGD LAB 
Entire LEW segment 
10: 70752452 to 
70868736  
173 224/50 
Region 4 
10: 70801867 to 
70868736 
163 202/43 
Table 4.2 Number of variations between S and LEW within the introgressed 
LEW segment and within the QTL (region4) 
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In an attempt to prioritize candidates for BP regulation in the LEW segment of C7, 
a detailed bioinformatics analysis generated no known annotation on rat chromosome 10 
(RNO10: 70752452bp to 70868736bp) whereas in homologous region on mouse 
chromosome 11 (MMU11) there was a novel long non-coding RNA LnC RNA- GM11426 
at position 11:82633353-82636309 and in human chromosome 17 (HSA 17) there was 
NOVEL LnC RNA (CODING GENE) - RP11-642M2.1 at position 17:33164890-33186065 
(Table A.2). Characterization or functional studies of either of these novel Lnc RNA has 
not been done as of now. Hypothesizing that a similar LnC RNA is present in the LEW 
segment in C7, we designed several primers but inspite of several modifications in PCR 
conditions and using various different sets of primers, we could not isolate any mRNA 
expressed from S, LEW or C7 strains (A.3). Further, to check if the expression of the 
adjacent genes was altered due to the presence of a regulator in this region, we did 
expression analysis for the genes Tmem132e and Cct6b genes (A.4). The results show that 
there was no significant differential expression in both of the adjacent genes, Tmem132e 
(heart p=0.96 and kidney p=0.29), Cct6b (heart p=0.17 and kidney p=0.87) compared to 
the heart and kidney samples of S rats on a high salt diet.  Since we were incapable of 
obtaining evidence of presence of a regulator we hypothesized this genomic segment may 
be involved in RNA protein interaction (Table A.5). Real time experiments to observe for 
change in expression of the three genes that was given a high score by the prediction 
software (RPI seq) did not show any significant difference between the C7 and S (data not 
shown). This led to further hypothesize that the segment may be involved in promoter 
activity. Then we looked at promoter predictions in the genomic segment using the 
Promoter 2.0 prediction server and found four predicted segments. Luciferase assay was 
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conducted on these prediction and the results indicate that there is no promoter activity 
noted in these four predicted regions (A.6). 
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DISCUSSION 
 
The goal of this study was to make congenic substrains from parental strains 
S.LEW(10)x12x2x3x5 that contains the region 2 and to confirm the role of Rffl in 
regulation of BP [196, 240]. Even though this goal was not attained, a fourth region has 
been added along with the BP QTLs (region 1, 2 and 3). This region 4 may contain genetic 
elements that once independent from parental strain S.LEW(10)x12x2x3x5 promotes BP 
lowering effect as seen in strain C7.  
One of the reasons for the lack of substrains developed around the Rffl gene could 
be due to the presence of other important genes like Lig3 and Rad51 that play an important 
role in double strand break and repair mechanism. Hence lack of viable offsprings could 
be due to the presence of chromosomal segments called ‘recombination deserts’ or 
recombinationally suppressed regions of DNA where genetic recombination may lead to 
mutation, fixation or extinction of all allelic variants within an important haplotype that 
play a major role in survival.  [246-253] 
 
Overall the study resulted in the following findings:  
1. The LEW segment in the parental strain S.LEW(10)X12X2X3X5 (10:70752452 to 
71070581) shows a BP increasing effect compared to the hypertensive S rat 
indicating that the LEW genetic segment at this location are prohypertensive and 
causes the S rat BP to increase.  
2. The LEW segment in C7 (10:70752452 to 70868736) when isolated from the 
parental S.LEW(10)X12X2X3X5 showed a BP decreasing effect compared to the 
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hypertensive S rat strain. The C7 also showed a rescue from high UPE indicating 
improved kidney function and increased lifespan. This could indicate that this LEW 
segment that currently contains no known annotations contains a functional 
variant/s that could be switched on or off relative to the neighboring genes or other 
variants [254].  
3. Epistasis has been implicated as one of the major players in regulation of complex 
traits like essential hypertension, cancer, neurological disorders and cardiovascular 
disorders [194, 255-263]. Strong evidence of epistasis was observed between 
genetic elements on rat chromosome 10. To explain better, if we divide the LEW 
segment on the parental strain into three segments (Figure 4-8) - orange, blue and 
yellow. When the red color segment is present in the strain 
S.LEW(10)X12X2X3X5, there is a BP increasing effect, loss of the light blue and 
green segment in strain C7 causes the BP to be significantly lower than S. The 
presence of green segment or loss of red segment in S.LEW(10)X12X2X3X1 
causes the BP effect to be lost. The black segment in C5 may be ruled out not 
involved in BP regulation. Hence the light blue and yellow segments may contain 
genetic elements regulating BP but the effect of yellow segment is lost or negated 
when present in S.LEW(10)X12X2X3X5.   Hence if there is a BP regulating 
elements in either the light blue, green and yellow segments, interactions between 
them can lead to loss of function, gain of function or negating effect.   
4. The missing or phantom heritability is due, at least in part, to epistasis or gene–
gene interactions, which is yet to be explored in human and murine models. This 
study in the rat model is an example of one such interaction between genetic 
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elements from gene desert region with other genetic elements. The results are not 
only an example of the prevalence of epistasis in BP regulation but also strengthen 
the fact that SNPs within gene deserts as in C7 are important regulators of disease 
development and prevention [124, 264-267].  
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Figure 4-8 Epistasis Model for BP regulation. 
 The black bar on the left side shows the relevant section of the physical map of RNO10. The left side 
of this bar has the names of the SNPs in the form of (S/LEW) and the right side of the bar has the 
physical location of these SNPs in base pairs. Strains C5, C7, S.LEW(10)X12X2X3X5 and 
S.LEW(10)X12X2X3X1are shown. The LEW segment of S.LEW(10)X12X2X3X5 is red and light 
blue, that of S.LEW(10)X12X2X3 is black and green, C7 is dark blue and yellow and C5 is all black. 
The BP effects of respective strains are shown below. 
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Future Direction 
 
Spatial organization of chromatin structures plays an important role in transcription 
of genes. Enhancers and insulators that lie distally influence formation of protein 
mediated loops [268-272].  Many of these regulators may lie in gene deserts and 
variations in the epigenome associated with SNPs in gene deserts help define 
complex phenotypes and diseases [123, 124, 264, 273, 274]. Techniques like 
Chromosome Conformation Capture and Hi-C is being currently used to study the 
architecture of genomes [268, 275-277]. Any of these methods will be used in 
future to fine map the gene desert on C7 strain to assign a functional role in BP 
regulation.   
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Chapter 5 
Perspective  
 
 
High blood pressure (hypertension) is the most common risk factor for other 
diseases which in turn accounts for more morbidity and mortality than any other category 
of diseases. Within the near future, it is conceivable that advances in medical technology 
and basic science will allow for therapy predicated on an individual’s genetic profile and 
variants. 
Personalized medicine is based on the notion that all individuals are uniquely 
defined by their genome and the difference between health and disease is determined by 
their genetic makeup along with a blend of environmental factors. Hence understanding 
the mechanisms and roles of genetic elements and screening for variations within these 
elements helps to understand person’s predisposition to a disease and the susceptibility to 
environmental factors. This can change a person’s response to a given drug. But for 
common conditions like hypertension, the cause may be heterogeneous, with multiple 
genes involved and interacting with several environmental factors. Sorting out which 
characteristics in an individual patients profile can serve as a useful biomarkers in the 
detection, evaluation, treatment, and prevention of hypertension remains an arduous 
process. Although uniquely personalized medicine for each patient may not yet be 
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practical, progress can certainly be made towards an intermediate goal of identifying 
subgroups within the patient population with more homogeneous pathophysiology and 
greater likelihood of favorable responses to particular therapeutic and preventative 
interventions.  
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Appendix A 
 
 
A.1 Primers for amplification of microsatellite markers and SNPs 
Markers Primers Location (ver3.4) 
D10MCO84-F CCATGCCTCACAGTGTCAAGG 70757255 
D10MCO84-R TTTCCACCTCCACCTTTGGTC   
RNO10(71.8-72.0)4A-F GGCTTAGCCTACTGCCTGAC 71978689 
RNO10(71.8-72.0)4A-R CAAGAGAGCTGGACATGCAA   
RNO10(71.8-72.0)1B-F GGGACCCTGAATCCACTCAT 71181108 
RNO10(71.8-72.0)1B-R AAGAGCCATCATTAAAAACAGG   
D10Mco83-F TGGGCATATTGTGCTGGCTC 70725437 
D10Mco83-R GGCCCTGTCTCCTTAAACAAGG   
D10Rat58-F TTGAGGAGGCAGAGACATTG 71067496 
D10Rat58-R CCTTTGGATTCTTTGTCTCCC   
D10Mco147-F GCACAGGACCAGGTCTGAAT 71100513 
D10Mco147-R CTGAACTCTGGGCTTTGCTT   
RNO10(71.10-71.16)-5F TCGGTTCAAATATGCTCACG 71175155 
RNO10(71.10-71.16)-5R GCAAAAGAAACTGAAGTCCAGA   
RNO10(71.1-71.2)-3BF GGGAACACAGCTCTCTCCAG 71160976 
RNO10(71.1-71.2)-3BR GGACCTGTAAGGTGTGTGTGG   
RNO10(71.1-71.2)-2-F ACCCACTCAGGGTAAGCAAA 71154003 
RNO10(71.1-71.2)-2-R TGGCTCTTTCCTCCCTACCT   
D10Mco43-F CTGGGAAGCAGAGTCTTGCTGG 71,476,900 
D10Mco43-R TCTGTGCAAGCCTTCATCTTACTG   
D10Got88-F CTCGATCGTATCCGGCAT 71,662,574 
D10Got88-R CGATCCCCAGAACCTACATAA   
D10Mco62-F TGATCTCCACAAACATGCCACAGT 72063232 
   
D10Mco62-R GACGGAGAGCCCAGCGAACAC   
SNP (T/G)-F CTGTTGATGATGCTCAGATGG 71169252 
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SNP (T/G)-R TGATAGACAGGCATCCTCCTG   
SNP (C/T)-F CGTCGCTTCTGTTCTATATCCTT 71170090 
SNP (C/T)-R TATGGCAGCTCACAACCATC   
SNP (C/T)-F AAAGCTGTCTTTGGTTTTGTCC 71173406 
SNP (C/T)-R AGGATTGGGACATTGTTTGG   
SNP (T/G)-F TGGCTTCGAATTCACTGTGT 71545930 
SNP (T/G)-R TCTTAAACACTCAGCCCAGTACC   
SNP (A/G)-F AGGAAAGGGATCAGGAGTCA 71921657 
SNP (A/G)-R TTTGTGCATTTGGTGTTTTGA   
SNP (C/T)-F GATAAGTGGAGGGCTTTTTCC 72056728 
SNP (C/T)-R GGGCCTTTAGGGATTTGACA   
SNP (C/T)-F GCCACTTCTAAAGTTGCTCCA 72063014 
SNP (C/T)-R CCACTATGTAGGTCCCACAGG   
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A.2 Bioinformatics analysis of S.LEW(10)x12x2x3x5x1 (C7).  
 
 
 
  
 LOCATION ANNOTATIONS 
RAT  RNO 10: 
70,752,452-
70,868,736 
(RGSC 3.4)  
D4A2A4_RAT 
10:70825997-70826298 (version 3.4)  
NO ANNOTATIONS 
(RGSC 5.0) 
HUMAN HSA17: 
33080197-
33229548 
LnC RNA (CODING GENE)- 
RP11-642M2.1 
17:33164890-33186065 
MOUSE MMU11: 
82559640-
82694604 
LnC RNA (CODING GENE)- GM11426  
11:82633353-82636309 
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A.4 Expression of Tmem132e and Cct6b transcripts from heart and kidney tissues of 
54 days old animals of C7 were detected by RT-PCR. (Male rats, n=3 on 2% NaCl diet) 
the data shown is relative to the S rat assuming that S transcript level = 1  
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A.5 List of genes that are predicted for RNA-protein interaction on strain C7. The list 
is arranged not by the prediction numbers but the gene names. 
 
 
 
 
# Protein ID RNA ID 
35 ABEC1_MOUSE_16-178  rna_1_2056-2214 
103 ABEC1_MOUSE_16-178  rna_1_2043-2214 
5 ABEC2_MOUSE_53-225  rna_1_2056-2214 
6 ABEC2_MOUSE_53-225  rna_1_2043-2214 
14 ABEC2_MOUSE_53-225  rna_1_2048-2210 
28 ABEC2_MOUSE_53-225  rna_1_2036-2221 
54 ABEC2_MOUSE_53-225  rna_1_2060-2214 
4 ABEC3_MOUSE_238-408 rna_1_2056-2214 
16 ABEC3_MOUSE_238-408 rna_1_2043-2214 
23 ABEC3_MOUSE_238-408 rna_1_2048-2210 
30 ABEC3_MOUSE_238-408 rna_1_2060-2214 
10 AICDA_MOUSE_12-181  rna_1_2056-2214 
19 AICDA_MOUSE_12-181  rna_1_2043-2214 
37 AICDA_MOUSE_12-181  rna_1_2048-2210 
53 AICDA_MOUSE_12-181  rna_1_2060-2214 
108 AICDA_MOUSE_12-181  rna_1_2036-2221 
110 CNOT8_MOUSE_14-241 rna_1_2056-2214 
44 DICER_MOUSE_1314-1573 rna_1_2060-2214 
45 DICER_MOUSE_1314-1573 rna_1_2056-2214 
76 DPOE1_MOUSE_273-438 rna_1_2056-2214 
32 ENDOU_MOUSE_137-408 rna_1_2056-2214 
99 ENDOU_MOUSE_137-408 rna_1_2060-2214 
101 EXOSX_MOUSE_289-457 rna_1_2056-2214 
49 FAKD1_MOUSE_560-631 rna_1_2056-2214 
104 FGGY_MOUSE_13-270  rna_1_2060-2214 
75 FGGY_MOUSE_291-499  rna_1_2056-2214 
13 FXR2_MOUSE_372-530 rna_1_2056-2214 
36 FXR2_MOUSE_372-530 rna_1_2060-2214 
116 GEMI6_MOUSE_2-168  rna_1_2056-2214 
117 GEMI6_MOUSE_2-168  rna_1_2043-2214 
31 GLPK_MOUSE_13-274 rna_1_2060-2214 
50 GLPK_MOUSE_13-274 rna_1_2056-2214 
95 GLPK_MOUSE_13-274 rna_1_2069-2214 
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77 GLPK2_MOUSE_13-268  rna_1_2060-2214 
78 GLPK2_MOUSE_13-268  rna_1_2056-2214 
1 GLPK5_MOUSE_26-289  rna_1_2056-2214 
2 GLPK5_MOUSE_26-289  rna_1_2060-2214 
17 GLPK5_MOUSE_26-289  rna_1_2048-2210 
46 GLPK5_MOUSE_26-289  rna_1_2043-2214 
58 GLPK5_MOUSE_26-289  rna_1_2069-2214 
91 GLPK5_MOUSE_26-289  rna_1_2067-2214 
106 HNRDL_MOUSE_32-99 rna_1_2056-2214 
72 HNRH1_MOUSE_14-84  rna_1_2056-2214 
67 HNRH2_MOUSE_14-84  rna_1_2056-2214 
105 HNRPF_MOUSE_292-358  rna_1_2056-2214 
34 LARP7_MOUSE_122-183 rna_1_2056-2214 
33 LARP7_MOUSE_122-184 rna_1_2056-2214 
65 LRRF1_MOUSE_24-287 rna_1_2060-2214 
48 
MARF1_MOUSE_1089-
1151 rna_1_2056-2214 
47 
MARF1_MOUSE_1249-
1318 rna_1_2056-2214 
43 MK67I_MOUSE_50-116 rna_1_2056-2214 
85 MK67I_MOUSE_50-120 rna_1_2056-2214 
26 MPP10_MOUSE_18-659 rna_1_2018-2209 
60 MPP10_MOUSE_18-659 rna_1_2021-2214 
92 MPP10_MOUSE_18-659 rna_1_2015-2214 
68 MSH6_MOUSE_537-697 rna_1_2056-2214 
102 MSH6_MOUSE_537-697 rna_1_2043-2214 
120 NAT10_MOUSE_282-490 rna_1_2056-2214 
79 NT5C_MOUSE_6-199 rna_1_2056-2214 
71 NUCL_MOUSE_572-639  rna_1_2056-2214 
64 OAS1B_MOUSE_159-347  rna_1_2056-2214 
70 PABP1_MOUSE_102-170 rna_1_2056-2214 
25 PAN2_MOUSE_975-1148 rna_1_2056-2214 
59 PAN2_MOUSE_975-1148 rna_1_2043-2214 
20 PIWL1_MOUSE_557-850 rna_1_2060-2214 
21 PIWL1_MOUSE_557-850 rna_1_2056-2214 
56 PIWL2_MOUSE_667-958 rna_1_2060-2214 
57 PIWL2_MOUSE_667-958 rna_1_2056-2214 
89 PIWL4_MOUSE_542-835 rna_1_2060-2214 
90 PIWL4_MOUSE_542-835 rna_1_2056-2214 
81 PPIL4_MOUSE_243-313 rna_1_2056-2214 
115 PPIL4_MOUSE_243-314 rna_1_2056-2214 
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18 PR38B_MOUSE_44-235 rna_1_2056-2214 
62 PR38B_MOUSE_44-235 rna_1_2043-2214 
51 PURA_MOUSE_58-279  rna_1_2056-2214 
69 PURA_MOUSE_58-279  rna_1_2060-2214 
3 PURB_MOUSE_44-293  rna_1_2060-2214 
7 PURB_MOUSE_44-293  rna_1_2056-2214 
9 PURB_MOUSE_44-293  rna_1_2069-2214 
12 PURB_MOUSE_44-293  rna_1_2067-2214 
52 PURB_MOUSE_44-293  rna_1_2048-2210 
73 PURB_MOUSE_44-293  rna_1_2089-2220 
74 PURB_MOUSE_44-293  rna_1_2080-2218 
24 PURG_MOUSE_61-326  rna_1_2056-2214 
88 PURG_MOUSE_61-326  rna_1_2060-2214 
118 RBM18_MOUSE_42-106 rna_1_2056-2214 
55 RNH2A_MOUSE_32-243  rna_1_2056-2214 
40 RNT2_MOUSE_40-220 rna_1_2056-2214 
82 RNT2_MOUSE_40-220 rna_1_2043-2214 
39 RPC5_MOUSE_5-435  rna_1_2060-2214 
80 RPC5_MOUSE_5-435  rna_1_2056-2214 
119 SF3B4_MOUSE_16-87 rna_1_2056-2214 
15 SHPK_MOUSE_7-263 rna_1_2060-2214 
22 SHPK_MOUSE_7-263 rna_1_2056-2214 
112 SHPK_MOUSE_7-263 rna_1_2069-2214 
113 SHPK_MOUSE_7-263 rna_1_2067-2214 
111 SLIRP_MOUSE_22-91  rna_1_2056-2214 
8 SMG7_MOUSE_172-431 rna_1_2060-2214 
11 SMG7_MOUSE_172-431 rna_1_2056-2214 
96 SMG7_MOUSE_172-431 rna_1_2069-2214 
97 SMG7_MOUSE_172-431 rna_1_2067-2214 
98 SMG7_MOUSE_172-431 rna_1_2048-2210 
27 SMN_MOUSE_24-287 rna_1_2056-2214 
100 SMN_MOUSE_24-287 rna_1_2060-2214 
109 SRS10_MOUSE_13-83 rna_1_2056-2214 
107 STAU1_MOUSE_98-163  rna_1_2056-2214 
41 TCAL1_MOUSE_2-166 rna_1_2056-2214 
42 TCAL1_MOUSE_2-166 rna_1_2043-2214 
83 THYN1_MOUSE_57-221 rna_1_2056-2214 
84 THYN1_MOUSE_57-221 rna_1_2043-2214 
29 TOE1_MOUSE_38-456 rna_1_2060-2214 
38 TOE1_MOUSE_38-456 rna_1_2056-2214 
114 TOE1_MOUSE_38-456 rna_1_2069-2214 
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94 TRA2A_MOUSE_120-191  rna_1_2056-2214 
63 TRA2A_MOUSE_122-191  rna_1_2056-2214 
93 TSAP1_MOUSE_99-160 rna_1_2056-2214 
61 TSAP1_MOUSE_99-163 rna_1_2056-2214 
87 VIGLN_MOUSE_225-286 rna_1_2056-2214 
86 VIGLN_MOUSE_730-791 rna_1_2056-2214 
66 XYLB_MOUSE_311-497 rna_1_2056-2214 
 total=46 genes  
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A.6- Luciferase activity (for predicted promoters) was expressed as relative 
values to those generated by empty vector PGL3. HRK-293 cell lines were 
cotransfected with the PGL3 vector containing the inserted predicted promoter 
region. After 24 hours of transfection, the cells were harvested and luciferase 
activity was determined. The values are normalized to Renilla expression.  
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